
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Comput. Biol</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27716836</article-id><article-id pub-id-type="pmc">5055357</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1005135</article-id><article-id pub-id-type="publisher-id">PCOMPBIOL-D-16-00721</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Interactions</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Interactions</subject><subj-group><subject>Drug-Drug Interactions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Applied Mathematics</subject><subj-group><subject>Algorithms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Simulation and Modeling</subject><subj-group><subject>Algorithms</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Research and Development</subject><subj-group><subject>Drug Discovery</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (Mathematics)</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme Inhibitors</subject><subj-group><subject>Kinase Inhibitors</subject><subj-group><subject>Tyrosine Kinase Inhibitors</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Biological Databases</subject><subj-group><subject>Genomic Databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genome Analysis</subject><subj-group><subject>Genomic Databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Analysis</subject><subj-group><subject>Genomic Databases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing</article-title><alt-title alt-title-type="running-head">Large-Scale Off-Target Prediction and Drug Repurposing</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8420-4750</contrib-id><name><surname>Lim</surname><given-names>Hansaim</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Poleksic</surname><given-names>Aleksandar</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tong</surname><given-names>Hanghang</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0719-8289</contrib-id><name><surname>He</surname><given-names>Di</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3892-384X</contrib-id><name><surname>Zhuang</surname><given-names>Luke</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff007"><sup>7</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>The Graduate Center, The City University of New York, New York, New York, United States</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Computer Science, University of Northern Iowa, Cedar Falls, Iowa, United States</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Computer Science and Technology, Nanjing University, Nanjing, Jiangsu, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>School of Computing, Informatics and Decision Systems Engineering, Arizona State University, Tempe, Arizona, United States</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Academy for Information Technology, Union County Vocational-Technical Schools, Scotch Plains, New Jersey, United States</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>High Technology High School, Lincroft, New Jersey, United States</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Department of Computer Science, Hunter College, The City University of New York, New York, New York, United States</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Schlessinger</surname><given-names>Avner</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Icahn School of Medicine at Mount Sinai, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceived and designed the experiments:</bold> LX HT.</p></list-item><list-item><p><bold>Performed the experiments:</bold> HL AP LX DH LZ PM.</p></list-item><list-item><p><bold>Analyzed the data:</bold> HL LX.</p></list-item><list-item><p><bold>Wrote the paper:</bold> HL LX.</p></list-item><list-item><p><bold>Implemented the software:</bold> YY HL.</p></list-item><list-item><p><bold>Designed the experiments:</bold> LX HL.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>lei.xie@hunter.cuny.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2016</year></pub-date><volume>12</volume><issue>10</issue><elocation-id>e1005135</elocation-id><history><date date-type="received"><day>4</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>8</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Lim et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Lim et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pcbi.1005135.pdf"/><abstract><p>Target-based screening is one of the major approaches in drug discovery. Besides the intended target, unexpected drug off-target interactions often occur, and many of them have not been recognized and characterized. The off-target interactions can be responsible for either therapeutic or side effects. Thus, identifying the genome-wide off-targets of lead compounds or existing drugs will be critical for designing effective and safe drugs, and providing new opportunities for drug repurposing. Although many computational methods have been developed to predict drug-target interactions, they are either less accurate than the one that we are proposing here or computationally too intensive, thereby limiting their capability for large-scale off-target identification. In addition, the performances of most machine learning based algorithms have been mainly evaluated to predict off-target interactions in the same gene family for hundreds of chemicals. It is not clear how these algorithms perform in terms of detecting off-targets across gene families on a proteome scale. Here, we are presenting a fast and accurate off-target prediction method, REMAP, which is based on a dual regularized one-class collaborative filtering algorithm, to explore continuous chemical space, protein space, and their interactome on a large scale. When tested in a reliable, extensive, and cross-gene family benchmark, REMAP outperforms the state-of-the-art methods. Furthermore, REMAP is highly scalable. It can screen a dataset of 200 thousands chemicals against 20 thousands proteins within 2 hours. Using the reconstructed genome-wide target profile as the fingerprint of a chemical compound, we predicted that seven FDA-approved drugs can be repurposed as novel anti-cancer therapies. The anti-cancer activity of six of them is supported by experimental evidences. Thus, REMAP is a valuable addition to the existing <italic>in silico</italic> toolbox for drug target identification, drug repurposing, phenotypic screening, and side effect prediction. The software and benchmark are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/hansaimlim/REMAP">https://github.com/hansaimlim/REMAP</ext-link>.</p></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>High-throughput techniques have generated vast amounts of diverse omics and phenotypic data. However, these sets of data have not yet been fully explored to improve the effectiveness and efficiency of drug discovery, a process which has traditionally adopted a one-drug-one-gene paradigm. Consequently, the cost of bringing a drug to market is astounding and the failure rate is daunting. The failure of the target-based drug discovery is in large part due to the fact that a drug rarely interacts only with its intended receptor, but also generally binds to other receptors. To rationally design potent and safe therapeutics, we need to identify all the possible cellular proteins interacting with a drug in an organism. Existing experimental techniques are not sufficient to address this problem, and will benefit from computational modeling. However, it is a daunting task to reliably screen millions of chemicals against hundreds of thousands of proteins. Here, we introduce a fast and accurate method REMAP for large-scale predictions of drug-target interactions. REMAP outperforms state-of-the-art algorithms in terms of both speed and accuracy, and has been successfully applied to drug repurposing. Thus, REMAP may have broad applications in drug discovery.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000092</institution-id><institution>U.S. National Library of Medicine</institution></institution-wrap></funding-source><award-id>R01LM011986</award-id><principal-award-recipient><name><surname>Xie</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>CNS-0958379</award-id></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>CNS-0855217</award-id></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>ACI-1126113</award-id></award-group><award-group id="award005"><funding-source><institution>UNI's Summer Fellowship</institution></funding-source><principal-award-recipient><name><surname>Poleksic</surname><given-names>Aleksandar</given-names></name></principal-award-recipient></award-group><funding-statement>This research was supported by the National Library of Medicine of the National Institute of Health under the award number R01LM011986 (LX), National Science Foundation under the award number CNS-0958379, CNS-0855217, ACI-1126113, and the City University of New York High Performance Computing Center at the College of Staten Island. AP is supported, in part, by the 2016 UNI&#x02019;s Summer Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="2"/><page-count count="26"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The software and benchmark data are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/hansaimlim/REMAP">https://github.com/hansaimlim/REMAP</ext-link>. All other relevant data are within the paper and its Supporting Information.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The software and benchmark data are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/hansaimlim/REMAP">https://github.com/hansaimlim/REMAP</ext-link>. All other relevant data are within the paper and its Supporting Information.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Conventional one-drug-one-gene drug discovery and drug development is a time-consuming and expensive process. It suffers from high attrition rate and possible unexpected post-market withdrawal [<xref rid="pcbi.1005135.ref001" ref-type="bibr">1</xref>]. It has been recognized that a drug rarely only binds to its intended target, and off-target interactions (i.e. interactions between the drug and unintended targets) are common [<xref rid="pcbi.1005135.ref002" ref-type="bibr">2</xref>]. The off-target interaction may lead to adverse drug reactions (ADRs) [<xref rid="pcbi.1005135.ref003" ref-type="bibr">3</xref>], as demonstrated by the deadly side effect of a Fatty Acid Amide Hydrolase (FAAH) inhibitor in a recent clinical trial [<xref rid="pcbi.1005135.ref004" ref-type="bibr">4</xref>]. On the other hand, the off-target interaction may be therapeutically useful, thus providing opportunities for drug repurposing and polypharmacology [<xref rid="pcbi.1005135.ref002" ref-type="bibr">2</xref>]. Therefore, identifying off-target interactions is an important step in drug discovery and development in order to reduce the drug attrition rate and to accelerate the drug discovery and development process, and ultimately to make safer and more affordable drugs.</p><p>Many efforts have been devoted to developing statistical machine learning methods for the prediction of unknown drug-target associations by screening large chemical and protein data sets [<xref rid="pcbi.1005135.ref005" ref-type="bibr">5</xref>]. One of the fundamental assumptions in applying statistical machine learning methods to drug-target interaction prediction is that similar chemicals bind to similar protein targets, and vice versa. Based on this similarity principle, both semi-supervised and supervised machine learning techniques have been applied. The semi-supervised learning methods either build statistical models for the <italic>k</italic> nearest neighbors (<italic>k-</italic>NN) of the query compound with similar compounds in the database (e.g. Parzen-Rosenblatt Window (PRW) [<xref rid="pcbi.1005135.ref006" ref-type="bibr">6</xref>] and Set Ensemble Analysis (SEA) [<xref rid="pcbi.1005135.ref007" ref-type="bibr">7</xref>] are examples). Although a large number of 2D and 3D fingerprint representations of chemical structures have been developed, chemical structure similarity that is measured by Tanimoto coefficient (TC) or other similarity metrics of fingerprints is not continuously correlated with the binding activity. Activity cliff exists in the chemical space, where a small modification of a chemical structure can lead to a dramatic change in binding activity [<xref rid="pcbi.1005135.ref008" ref-type="bibr">8</xref>]. Thus, the chemical structural similarity alone is not sufficient to capture genome-wide target binding profile, as protein-chemical interaction is determined by both protein structures and chemical structures. New deep learning techniques that can learn non-linear, hierarchical relationships may provide new solutions for representing chemical space [<xref rid="pcbi.1005135.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pcbi.1005135.ref012" ref-type="bibr">12</xref>]. However, few work has been done to incorporate protein relationships into the deep learning framework. It remains to be seen whether the deep learning is applicable to genome-wide target prediction.</p><p>A number of techniques such as Gaussian Interaction Profile (GIP), Weighted Nearest Neighbor (WNN), Regularized Least Squares (RLS) classifier [<xref rid="pcbi.1005135.ref013" ref-type="bibr">13</xref>, <xref rid="pcbi.1005135.ref014" ref-type="bibr">14</xref>], and matrix factorization [<xref rid="pcbi.1005135.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pcbi.1005135.ref017" ref-type="bibr">17</xref>] have been developed to integrate chemical and genomic space. Among them, Neighborhood Regularized Logistic Matrix Factorization (NRLMF) [<xref rid="pcbi.1005135.ref017" ref-type="bibr">17</xref>] and Kernelized Bayesian Matrix Factorization (KBMF) [<xref rid="pcbi.1005135.ref016" ref-type="bibr">16</xref>] are two of the most successful methods. However, several drawbacks in these algorithms hinder their applications in genome-wide off-target predictions. First, several algorithms with high performance such as KBMF are extremely time and memory-consuming. Second, these algorithms depend on a supervised learning framework that requires negative cases. While publicly available biological and/or chemical databases (e.g. ZINC [<xref rid="pcbi.1005135.ref018" ref-type="bibr">18</xref>], ChEMBL [<xref rid="pcbi.1005135.ref019" ref-type="bibr">19</xref>], DrugBank [<xref rid="pcbi.1005135.ref020" ref-type="bibr">20</xref>], PubChem [<xref rid="pcbi.1005135.ref021" ref-type="bibr">21</xref>], and UniProt [<xref rid="pcbi.1005135.ref022" ref-type="bibr">22</xref>]) have enabled large-scale screening of drug-target associations, the known chemical-protein associations are sparse, and the number of reported negative cases (i.e. chemical-protein pairs not associated) is too small to optimally train a prediction algorithm [<xref rid="pcbi.1005135.ref023" ref-type="bibr">23</xref>]. Using randomly generated negative cases will adversely impact the performance of these algorithms, and algorithmically derived negative cases are often based on unrealistic assumptions [<xref rid="pcbi.1005135.ref023" ref-type="bibr">23</xref>]. Finally, these algorithms have been mainly evaluated for the prediction of off-targets within the same gene family (e.g. GPCR) using a small benchmark with hundreds of drugs and targets. Their performances in predicting off-target across gene families on a large scale are uncertain. Indeed, drug cross-reactivity often occurs across fold spaces [<xref rid="pcbi.1005135.ref002" ref-type="bibr">2</xref>]. Thus, the development of <italic>in silico</italic> prediction methods that are fast as well as accurate enough to explore the available data is urgent.</p><p>Here, we make several contributions to address the aforementioned problems. First, we present an efficient method, REMAP, which formulates the off-target predictions as a dual-regularized One Class Collaborative Filtering (OCCF) problem. Thus, negative data are not needed for the training, but can be used if available. Secondly, REMAP is highly scalable with promising accuracy, thus can be applied to large-scale off-target predictions. Thirdly, we introduce a new benchmark set to evaluate the performance of drug-target interactions across gene families. Finally, we apply REMAP to repurposing existing drugs for new diseases. We identified seven drugs that have anti-cancer activity. Six of them are supported by experimental evidence.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Problem formulation</title><p>The problem we try to solve here is to predict how likely it is that a chemical interacts with a target protein, using a chemical-protein association network, chemical-chemical similarity, and protein-protein similarity information. We start by preparing a bipartite network for chemical-protein associations as a sparse <italic>n</italic> &#x000d7; <italic>m</italic> matrix <italic>R</italic>, where <italic>n</italic> is the number of chemicals and <italic>m</italic> is the number of proteins. <italic>R</italic><sub><italic>i</italic>,<italic>j</italic></sub> = 1 if the <italic>i</italic><sup><italic>th</italic></sup> chemical is associated with the <italic>j</italic><sup><italic>th</italic></sup> protein, and <italic>R</italic><sub><italic>i</italic>,<italic>j</italic></sub> = 0, otherwise. The chemical-chemical similarity scores are in an <italic>n</italic> &#x000d7; <italic>n</italic> square matrix <italic>C</italic>, with <italic>C</italic><sub><italic>i</italic>,<italic>j</italic></sub> representing the chemical-chemical similarity score between the <italic>i</italic><sup><italic>th</italic></sup> and <italic>j</italic><sup><italic>th</italic></sup> chemicals (0 &#x02264; <italic>C</italic><sub><italic>i</italic>,<italic>j</italic></sub> &#x02264; 1) for total <italic>n</italic> chemicals. The protein-protein similarity scores are in the same format for total <italic>m</italic> proteins (0 &#x02264; <italic>T</italic><sub><italic>i</italic>,<italic>j</italic></sub> &#x02264; 1). We consider this problem an analog of user-item preferences such that users and items represent chemicals and proteins, respectively. Therefore, the problem is to provide an <italic>n</italic> &#x000d7; <italic>m</italic> matrix <italic>P</italic> in which <italic>P</italic><sub><italic>i</italic>,<italic>j</italic></sub> is the prediction score for the interaction between the <italic>i</italic><sup><italic>th</italic></sup> chemical and the <italic>j</italic><sup><italic>th</italic></sup> protein.</p></sec><sec id="sec004"><title>Overview of off-target prediction method REMAP</title><p>Our prediction method REMAP is based on a one-class collaborative filtering algorithm that recommends the users&#x02019; preferences to the listed items [<xref rid="pcbi.1005135.ref024" ref-type="bibr">24</xref>]. It assumes that similar users will prefer similar items, unobserved associations are not necessarily negative, and user-item preferences can be analogous to drug-target associations. Assuming that a fairly low number of factors (i.e. smaller number of features than the number of total chemicals or protein targets) may capture the characteristics determining the chemical-protein associations, two low-rank matrices, <italic>U</italic> (chemical side) and <italic>V</italic> (protein side), were approximated such that <inline-formula id="pcbi.1005135.e001"><alternatives><graphic xlink:href="pcbi.1005135.e001.jpg" id="pcbi.1005135.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:mstyle displaystyle="true"><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:msubsup><mml:mrow><mml:mstyle displaystyle="true"><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mi>j</mml:mi><mml:mi>m</mml:mi></mml:msubsup><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mi>R</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>U</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>V</mml:mi><mml:mi>T</mml:mi></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula> is minimized where <italic>R</italic> is the matrix for known chemical-protein associations and <italic>V</italic><sup><italic>T</italic></sup> is the transposition of the protein side low-rank matrix <italic>V</italic>. The two low rank matrices, <italic>U</italic><sub><italic>n&#x000d7;r</italic></sub> and <italic>V</italic><sub><italic>m&#x000d7;r</italic></sub> are obtained by iteratively minimizing the objective function,
<disp-formula id="pcbi.1005135.e002"><alternatives><graphic xlink:href="pcbi.1005135.e002.jpg" id="pcbi.1005135.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:msub><mml:mrow><mml:mtext>min</mml:mtext></mml:mrow><mml:mrow><mml:mi>U</mml:mi><mml:mo>,</mml:mo><mml:mi>V</mml:mi><mml:mo>&#x02265;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mstyle displaystyle="true"><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>w</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo>:</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>&#x022c5;</mml:mo><mml:msubsup><mml:mi>V</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mo>:</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>&#x02016;</mml:mo><mml:mi>U</mml:mi><mml:mo>&#x02016;</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>&#x02016;</mml:mo><mml:mi>V</mml:mi><mml:mo>&#x02016;</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>U</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>V</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi>T</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula></p><p>All symbols used in the paper are summarized in <xref rid="pcbi.1005135.t001" ref-type="table">Table 1</xref>, and the overall process of REMAP is in <xref ref-type="fig" rid="pcbi.1005135.g001">Fig 1</xref>. Here, <italic>p</italic><sub><italic>wt</italic></sub> is the penalty weight on the observed and unobserved associations which indicate the reliability of the assigned probability of true association, <italic>p</italic><sub><italic>imp</italic></sub> is the imputed value (i.e. the probability of unobserved associations as real associations), <italic>p</italic><sub><italic>reg</italic></sub> is the regularization parameter to prevent overfitting, <italic>p</italic><sub><italic>chem</italic></sub> is the importance parameter for chemical-chemical similarity, <italic>p</italic><sub><italic>prot</italic></sub> is the importance parameter for protein-protein similarity, and <italic>tr</italic>(A) is the trace of matrix A (<xref rid="pcbi.1005135.t001" ref-type="table">Table 1</xref>). In this study, we use global weight and imputation. However, the weight and imputation values may be determined by <italic>a priori</italic> knowledge or from the prediction of other machine learning algorithms (i.e. <italic>p</italic><sub><italic>wt</italic></sub> and <italic>p</italic><sub><italic>imp</italic></sub> can be matrices with the same dimension as the matrix <italic>R</italic>). The raw predicted score for the <italic>i</italic><sup><italic>th</italic></sup> chemical to bind the <italic>j</italic><sup><italic>th</italic></sup> protein can be calculated by <inline-formula id="pcbi.1005135.e003"><alternatives><graphic xlink:href="pcbi.1005135.e003.jpg" id="pcbi.1005135.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>U</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo>:</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>&#x022c5;</mml:mo><mml:msubsup><mml:mi>V</mml:mi><mml:mrow><mml:mi>U</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mo>:</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. The raw scores were adjusted based on the ratio of observed positive and negative cases when the negative data are available (explained in the prediction score adjustment section). Also, the matrix <italic>U</italic><sub><italic>n&#x000d7;r</italic></sub> is referred to as a low-rank drug profile since its <italic>i</italic><sup><italic>th</italic></sup> row represents the <italic>i</italic><sup><italic>th</italic></sup> drug&#x02019;s behavior in the drug-target interaction network as well as drug-drug similarity spaces compressed to <italic>r</italic> number of features. The REMAP code was originally written in Matlab and modified for drug-target predictions.</p><table-wrap id="pcbi.1005135.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.t001</object-id><label>Table 1</label><caption><title>The symbols and the descriptions for numerical calculations</title></caption><alternatives><graphic id="pcbi.1005135.t001g" xlink:href="pcbi.1005135.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Symbol</th><th align="center" rowspan="1" colspan="1">Definition and Description</th></tr></thead><tbody><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>R</italic></td><td align="left" rowspan="1" colspan="1">The adjacency matrix of the known drug-target associations</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>C</italic>, <italic>T</italic></td><td align="left" rowspan="1" colspan="1">The chemical-chemical and the target-target similarity matrices</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><inline-formula id="pcbi.1005135.e004"><alternatives><graphic id="pcbi.1005135.e004g" xlink:href="pcbi.1005135.e004"/><mml:math id="M4"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x000a0;</mml:mi><mml:mo mathvariant="bold">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow><mml:mrow><mml:mn mathvariant="bold">1</mml:mn></mml:mrow></mml:msub><mml:mo mathvariant="bold">,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow><mml:mrow><mml:mn mathvariant="bold">2</mml:mn></mml:mrow></mml:msub><mml:mo mathvariant="bold">)</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">The chemical-chemical similarity score for the chemicals <italic>c</italic><sub>1</sub> and <italic>c</italic><sub>2</sub></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><inline-formula id="pcbi.1005135.e005"><alternatives><graphic id="pcbi.1005135.e005g" xlink:href="pcbi.1005135.e005"/><mml:math id="M5"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>&#x000a0;</mml:mi><mml:mo mathvariant="bold">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow><mml:mrow><mml:mn mathvariant="bold">1</mml:mn></mml:mrow></mml:msub><mml:mo mathvariant="bold">,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow><mml:mrow><mml:mn mathvariant="bold">2</mml:mn></mml:mrow></mml:msub><mml:mo mathvariant="bold">)</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">The Tanimoto dissimilarity coefficient for the chemicals <italic>c</italic><sub>1</sub> and <italic>c</italic><sub>2</sub></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>T</italic><sub>(<italic>p</italic>1,<italic>p</italic>2)</sub></td><td align="left" rowspan="1" colspan="1">The target-target similarity score for the query protein <italic>p</italic><sub>1</sub> and the target protein <italic>p</italic><sub>2</sub></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>d</italic><sub><italic>bit</italic>(<italic>p</italic>1,<italic>p</italic>2)</sub></td><td align="left" rowspan="1" colspan="1">The bit score for the query protein <italic>p</italic><sub>1</sub> and the target protein <italic>p</italic><sub>2</sub></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>D</italic><sub><italic>C</italic></sub>, <italic>D</italic><sub><italic>T</italic></sub></td><td align="left" rowspan="1" colspan="1">The degree matrices of <italic>C</italic> and <italic>T</italic>, respectively</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>U</italic>, <italic>V</italic></td><td align="left" rowspan="1" colspan="1">The chemical-side and the target-side low-rank approximation matrices</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>R</italic><sub>(<italic>i</italic>,<italic>j</italic>)</sub></td><td align="left" rowspan="1" colspan="1">The element of <italic>R</italic> at its <italic>i</italic><sup><italic>th</italic></sup> row and <italic>j</italic><sup><italic>th</italic></sup> column</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>R</italic><sub>(<italic>i</italic>,;)</sub></td><td align="left" rowspan="1" colspan="1">The <italic>i</italic><sup><italic>th</italic></sup> row of <italic>R</italic></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>R</italic><sub>(;,<italic>j</italic>)</sub></td><td align="left" rowspan="1" colspan="1">The <italic>j</italic><sup><italic>th</italic></sup> column of <italic>R</italic></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>R</italic><sup><italic>T</italic></sup></td><td align="left" rowspan="1" colspan="1">The transpose matrix of <italic>R</italic></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>tr</italic>(<italic>R</italic>)</td><td align="left" rowspan="1" colspan="1">The trace of <italic>R</italic></td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>p</italic><sub><italic>wt</italic></sub></td><td align="left" rowspan="1" colspan="1">The penalty weight on observed and unobserved associations which indicate the reliability of assigned probability of true association</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>p</italic><sub><italic>imp</italic></sub></td><td align="left" rowspan="1" colspan="1">The imputed value (i.e. the probability of unobserved associations as real associations</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>p</italic><sub><italic>reg</italic></sub></td><td align="left" rowspan="1" colspan="1">The regularization parameter to prevent overfitting</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>p</italic><sub><italic>chem</italic></sub></td><td align="left" rowspan="1" colspan="1">The importance parameter for chemical-chemical similarity</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>p</italic><sub><italic>prot</italic></sub></td><td align="left" rowspan="1" colspan="1">The importance parameter for protein-protein similarity</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>r</italic></td><td align="left" rowspan="1" colspan="1">The rank of the low-rank approximation matrices</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>p</italic><sub><italic>iter</italic></sub></td><td align="left" rowspan="1" colspan="1">The number of maximum iterations to minimize the objective function</td></tr><tr><td align="justify" style="background-color:#F2F2F2" rowspan="1" colspan="1"><italic>p</italic><sub>(<italic>i</italic>,<italic>j</italic>)</sub></td><td align="left" rowspan="1" colspan="1">The raw prediction score by REMAP for the <italic>i</italic><sup><italic>th</italic></sup> chemical and the <italic>j</italic><sup><italic>th</italic></sup> protein</td></tr></tbody></table></alternatives></table-wrap><fig id="pcbi.1005135.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g001</object-id><label>Fig 1</label><caption><title>The overall process of REMAP. The rectangular boxes with capitalized symbols are matrices, and the smaller boxes and ovals are chemicals and proteins, respectively, in the simplified network representation (top-left corner).</title><p>Solid lines within the network represent connectivity (edges), and the arrows represent mathematical processes. Red squares represent single similarity values, and blue bars in U and V represent row and column vectors. Lower-case c and p represents chemicals and proteins, respectively. The letter symbols are annotated in <xref rid="pcbi.1005135.t001" ref-type="table">Table 1</xref>.</p></caption><graphic xlink:href="pcbi.1005135.g001"/></fig></sec><sec id="sec005"><title>Chemical-chemical similarity</title><p>Chemical-chemical similarity scores are one of the required inputs of REMAP. Although there are a number of metrics developed for chemical-chemical similarity, a recent study showed that Tanimoto coefficient-based similarity is highly efficient for fingerprint-based similarity measurement [<xref rid="pcbi.1005135.ref025" ref-type="bibr">25</xref>]. The fingerprint of choice in this study is the Extended Connectivity Fingerprint (ECFP), which has been successfully applied to chemical structure-based target prediction method, PRW [<xref rid="pcbi.1005135.ref006" ref-type="bibr">6</xref>]. Thus, it allows for a fair comparison of REMAP with PRW. It is interesting to compare the different fingerprints in the future study.</p><p>To calculate a similarity score between two chemicals, c<sub>1</sub> and c<sub>2</sub>, the Tanimoto dissimilarity coefficient <inline-formula id="pcbi.1005135.e006"><alternatives><graphic xlink:href="pcbi.1005135.e006.jpg" id="pcbi.1005135.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>&#x000a0;</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> was obtained using JChem with the Tanimoto metric for the ECFP descriptor type using the command in the Unix environment, &#x0201c;<monospace><italic>ChemAxon/JChem/bin/screenmd target_smi query_smi -k ECFP -g -c -M Tanimoto</italic></monospace>&#x0201d; [<xref rid="pcbi.1005135.ref026" ref-type="bibr">26</xref>]. The chemical-chemical similarity score, <inline-formula id="pcbi.1005135.e007"><alternatives><graphic xlink:href="pcbi.1005135.e007.jpg" id="pcbi.1005135.e007g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M7"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x000a0;</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> is defined as <inline-formula id="pcbi.1005135.e008"><alternatives><graphic xlink:href="pcbi.1005135.e008.jpg" id="pcbi.1005135.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x000a0;</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mi>&#x000a0;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x000a0;</mml:mi><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>&#x000a0;</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>. Briefly, two chemicals have a higher similarity score if they have more of the same chemical moieties (e.g. functional groups) at more similar relative positions. Chemical similarity scores below 0.5 were treated as noise and set to 0.</p></sec><sec id="sec006"><title>Protein-protein similarity</title><p>Protein-protein similarity scores are also one of the required inputs for REMAP. The similarity between two proteins was calculated based on their sequence similarity using NCBI BLAST [<xref rid="pcbi.1005135.ref027" ref-type="bibr">27</xref>] with an e-value threshold of 1 &#x000d7; 10<sup>&#x02212;5</sup> and its default options (e.g. 11 for gap open penalty and 1 for its extension, BLOSUM62 for the scoring matrix, and so on). Based on our 10-fold cross validation (see below), e-value thresholds from 1 to 1 &#x000d7; 10<sup>&#x02212;20</sup> did not significantly affect the performance (<xref ref-type="supplementary-material" rid="pcbi.1005135.s001">S1 Fig</xref>). Therefore, we decided to use a moderately stringent threshold (BLAST default is 1 &#x000d7; 10<sup>&#x02212;3</sup>). A similarity score for query protein <italic>p</italic><sub>1</sub> to target protein <italic>p</italic><sub>2</sub> was calculated by the ratio of a bit score for the pair compared to the bit score of a self-query. To be specific, for the query protein <italic>p</italic><sub>1</sub> to the target protein <italic>p</italic><sub>2</sub>, protein-protein the similarity score was defined such that <italic>T</italic><sub>(<italic>p</italic>1,<italic>p</italic>2)</sub> = <italic>d</italic><sub><italic>bit</italic>(<italic>p</italic>1,<italic>p</italic>2)</sub>/<italic>d</italic><sub><italic>bit</italic>(<italic>p</italic>1,<italic>p</italic>1)</sub>.</p></sec><sec id="sec007"><title>Benchmark test and data preparation</title><p>For benchmark tests, ZINC data was filtered by IC<sub>50</sub> &#x02264; 10 &#x003bc;M, which yielded 31,735 unique chemical-protein associations for 12,384 chemicals and 3,500 proteins (ZINC dataset [<xref rid="pcbi.1005135.ref018" ref-type="bibr">18</xref>]). Targets that are protein complexes or cell-based tests were excluded. Proteins whose primary sequence is unavailable were also excluded. Protein sequences were obtained from UniProt [<xref rid="pcbi.1005135.ref022" ref-type="bibr">22</xref>], and the whole protein sequences were used to calculate protein-protein similarity scores.</p><p>To assess the predictive power of our algorithm, we performed a 10-fold cross validation on the ZINC dataset described above. We set the parameters as follows: <italic>p</italic><sub><italic>wt</italic></sub> = <italic>p</italic><sub><italic>imp</italic></sub> = <italic>p</italic><sub><italic>reg</italic></sub> = 0.1, <italic>r</italic> = 300, <italic>p</italic><sub><italic>chem</italic></sub> = 0.75, <italic>p</italic><sub><italic>prot</italic></sub> = 0.1, and <italic>p</italic><sub><italic>iter</italic></sub> = 400. The optimized values determined by the 10-fold cross validation of benchmark are shown in <xref ref-type="supplementary-material" rid="pcbi.1005135.s002">S2 Fig</xref>. It is noted that the best performance is achieved when <italic>p</italic><sub><italic>chem</italic></sub> = 0.25 and <italic>p</italic><sub><italic>prot</italic></sub> = 0.25. To further evaluate REMAP, we compared its performance on the ZINC dataset with several methods: a chemical similarity-based method (PRW [<xref rid="pcbi.1005135.ref006" ref-type="bibr">6</xref>]), the best performed matrix factorization methods so far (NRLMF [<xref rid="pcbi.1005135.ref017" ref-type="bibr">17</xref>] and KBMF with twin kernels (KBMF2K) [<xref rid="pcbi.1005135.ref016" ref-type="bibr">16</xref>]), combination of WNN and GIP (WNNGIP [<xref rid="pcbi.1005135.ref014" ref-type="bibr">14</xref>]), and another type of matrix factorization method (Collaborative Matrix Factorization (CMF) [<xref rid="pcbi.1005135.ref015" ref-type="bibr">15</xref>]) for different types of chemicals and proteins.</p><p>To obtain a detailed view of the performance of the methods, we divided the ZINC dataset into 3 categories with 2 subcategories for each, based on the connectivity of known chemical-protein associations and the degree of uniqueness of the chemicals. First, all the chemicals in the dataset were classified into the chemicals having only one known target (NT1), two known targets (NT2), or three or more known targets (NT3). Then, for the chemicals in each category, they were further divided based on either the number of known chemicals (ligands) the target proteins are associated with (number of ligands in increments of 5) or the maximum chemical-chemical similarity score for the chemical in the dataset (the similarity score range increment is 0.1). The label used in this paper for the dataset are NT<italic>a</italic>L<italic>b</italic>, or NT<italic>a</italic>MaxTc<italic>d</italic>, where &#x02018;NT&#x02019; stands for the Number of known Target, &#x02018;L&#x02019; for the number of known Ligand, and &#x02018;Tc&#x02019; for the maximum (Tanimoto coefficient-based) chemical-chemical similarity score for the given chemical in the dataset, with NT = <italic>a</italic>, <italic>b</italic> &#x02264; L &#x02264; <italic>b</italic> +4, and <italic>d</italic> &#x02212; 0.1 &#x0003c; Tc &#x02264; <italic>d</italic>. For instance, NT2L1 is the data set label for chemicals having two known targets and proteins having 1 to 5 ligands in the dataset, and NT1Tc0.9 is for chemicals with the most similar chemicals between 0.8 and 0.9 of similarity scores and having one known target. Chemicals having more than three known targets are included in the NT3 class, and proteins having more than twenty-one known ligands were included in L21 (not limited to 25). The categories of the ZINC dataset were then used to evaluate the performance of off-target prediction, and their labels mean the number of known ligands (L) or the maximum structural similarity (Tc) with their corresponding ranges. For example, &#x02018;L21more&#x02019; stands for the dataset for proteins having 21 or more known targets, and &#x02018;Tc0.9to1.0&#x02019; stands for maximum structural similarity greater than 0.9 and up to 1.0 (Tc0.5to0.6 is inclusive of 0.5). Note that NT1 is equivalent to chemicals without any known target when they are tested for cross validation. Therefore, performances on NT1 datasets reflect the ability to address the <italic>cold start</italic> problem. In other words, when one known drug-target association is intentionally hidden for the chemicals in the NT1 dataset, the tested chemicals will not have any known target in the training data, and they are less likely to be given a good recommendation of targets. This is analogous to the <italic>new user or new item</italic> problem reviewed by Su et al. [<xref rid="pcbi.1005135.ref028" ref-type="bibr">28</xref>].</p></sec><sec id="sec008"><title>Measuring prediction accuracy of REMAP by TPR <italic>vs</italic>. cutoff rank</title><p>A typical measure of prediction performance is the Receiver Operating Characteristic (ROC) curve by which one can assess the reliability of the positively predicted results. However, it is difficult to apply the ROC curve on our chemical-protein association datasets since the vast majority of the chemical-protein pairs have not been tested, and thus it is unclear whether the missing entries are actually unassociated or just not yet observed.</p><p>In order to assess how reliable the positively predicted results from REMAP are, we needed to define a performance measurement that is analogous to ROC curve but not dependent on the true negatives. Our primary measure of performance is the true positive rate (<inline-formula id="pcbi.1005135.e009"><alternatives><graphic xlink:href="pcbi.1005135.e009.jpg" id="pcbi.1005135.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>e</mml:mi><mml:mi>&#x000a0;</mml:mi><mml:mi>P</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>&#x000a0;</mml:mi><mml:mi>P</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfrac><mml:mo>;</mml:mo></mml:math></alternatives></inline-formula> Recall or Recovery) at the top 1% of predictions for each chemical. To be specific, the top 1% of predictions includes up to the 35<sup>th</sup>-ranked predicted target protein for a chemical for our datasets (3,500 possible target proteins for each chemical). Thus, for instance, a TPR of 0.965 at the 35<sup>th</sup> cutoff rank (top 1%) means that 96.5% of the total tested positive pairs were ranked 35<sup>th</sup> or better for the tested chemicals.</p></sec><sec id="sec009"><title>Scalability of REMAP as a matrix factorization algorithm</title><p>In order to assess the speed of REMAP for practical uses, we measured its running time by varying the rank parameter or the size of dataset. On the ZINC dataset (12,384 chemicals and 3,500 proteins), up to <italic>r</italic> = 2,000 was tested, and at fixed <italic>r</italic> = 200, dataset sizes up to 200,000 chemicals and 20,000 proteins were tested. The number of iterations (<italic>p</italic><sub><italic>iter</italic></sub>) was fixed to 400. A single node of CPU with 2.88 GB of memory in the City University of New York High Performance Computing Center (CUNY HPCC) was used for REMAP running time tests. We also compared the running times of different matrix factorization methods with ours. Due to the large time complexity and memory requirement for other algorithms, a multi-core node with up to 700 GB of shared memory system in CUNY HPCC was used for them on the ZINC dataset.</p></sec><sec id="sec010"><title>Genome-wide chemical-protein associations</title><p>Chemical-protein associations were obtained from the ZINC [<xref rid="pcbi.1005135.ref018" ref-type="bibr">18</xref>], ChEMBL [<xref rid="pcbi.1005135.ref019" ref-type="bibr">19</xref>] and DrugBank [<xref rid="pcbi.1005135.ref020" ref-type="bibr">20</xref>] databases. To obtain reliable chemical-protein association pairs, binding assays records with IC<sub>50</sub> information were extracted from the databases, and the cutoff IC<sub>50</sub> value of 10 &#x003bc;M was used where applicable. Two chemicals were considered the same if their InChI Keys are identical, and two proteins were considered so if their UniProt Accessions are identical. For records with IC<sub>50</sub> in &#x003bc;g/L (found in ChEMBL), the full molecular weights of the compounds listed on ChEMBL were used to convert &#x003bc;g/L to &#x003bc;M. Chemical-protein pairs were considered associated if IC<sub>50</sub>&#x02264;10 &#x003bc;M (active pairs), unassociated if IC<sub>50</sub>&#x0003e;10 &#x003bc;M (inactive pairs), ambiguous if records exist in both ranges (ambiguous pairs), and unobserved otherwise (unknown pairs). A total of 198,712 unique chemicals and 3,549 unique target proteins were obtained from the combination of ChEMBL and ZINC with 228,725 unique chemical-protein active pairs, 76,643 inactive pairs, and 4,068 ambiguous pairs. Of the 198,712 chemicals, 722 were found to be FDA-approved drugs. Furthermore, drug-target relationships were extracted from the DrugBank and integrated into the ZINC_ChEMBL dataset above. A total of 199,338 unique chemicals and 6,277 unique proteins were obtained from the combination of ZINC, ChEMBL, and DrugBank with 233,378 unique chemical-protein active pairs.</p></sec><sec id="sec011"><title>Drug-target interaction profile analysis for drug repurposing</title><p>Since REMAP showed promising performances on predicting off-targets for chemicals with at least one known target, it is possible to use REMAP to suggest new purposes for some FDA approved drugs. As the matrix product of <italic>U</italic><sub><italic>UP</italic></sub> (chemical-side low-rank matrix) and <italic>V</italic><sub><italic>UP</italic></sub> (protein side low-rank matrix) is the predicted drug-target interaction matrix <italic>P</italic>, the <italic>i</italic><sup><italic>th</italic></sup> row of <italic>U</italic><sub><italic>UP</italic></sub> contains the target interaction profile for the <italic>i</italic><sup><italic>th</italic></sup> drug. Therefore, we analyzed the drug-drug similarities based on the low-rank matrix <italic>U</italic><sub><italic>UP</italic></sub>. We ran REMAP with the data combination of three databases explained above, with the parameters used in the benchmark evaluations. Then, we calculated drug-drug cosine similarities based on the matrix <italic>U</italic><sub><italic>UP</italic></sub>. For each row of <italic>U</italic><sub><italic>UP</italic></sub> for FDA approved drugs, the cosine similarity of drug c<sub>1</sub> and drug c<sub>2</sub> can be calculated by, <inline-formula id="pcbi.1005135.e010"><alternatives><graphic xlink:href="pcbi.1005135.e010.jpg" id="pcbi.1005135.e010g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M10"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mi>&#x000a0;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x000a0;</mml:mi><mml:mfrac><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>&#x02192;</mml:mo></mml:mover><mml:mo>&#x02219;</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>&#x02192;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msqrt><mml:mfenced close="|" open="|" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:msqrt><mml:msqrt><mml:mfenced close="|" open="|" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:msqrt></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>. To search for possibly undiscovered uses of the drugs, we focused on drugs that are found to have high cosine similarity but low Tanimoto similarity (&#x0003c; 0.5). Markov Cluster (MCL) Algorithm [<xref rid="pcbi.1005135.ref029" ref-type="bibr">29</xref>, <xref rid="pcbi.1005135.ref030" ref-type="bibr">30</xref>] was used to cluster drugs based on their cosine similarity of a low-rank target profile. Drug-disease associations were obtained from the Comparative Toxicogenomics Database (CTD) [<xref rid="pcbi.1005135.ref031" ref-type="bibr">31</xref>].</p></sec><sec id="sec012"><title>Prediction score adjustment</title><p>The raw prediction score (<inline-formula id="pcbi.1005135.e011"><alternatives><graphic xlink:href="pcbi.1005135.e011.jpg" id="pcbi.1005135.e011g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M11"><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mi>&#x000a0;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x000a0;</mml:mi><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mi>U</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo>:</mml:mo><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mo>&#x02219;</mml:mo><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>U</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mo>:</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>) can be adjusted to better reflect the real data as well as to statistically discriminate the positive and negative predictions. We used the active, inactive and ambiguous pairs obtained from the ChEMBL database to adjust the score. REMAP prediction on the ZINC_ChEMBL dataset showed a clear division between the active and inactive pairs, suggesting that predictions scored around 1.0 are highly likely to be positive (<xref ref-type="fig" rid="pcbi.1005135.g002">Fig 2A</xref>). As mentioned above, however, there is a large difference between the number of active and inactive pairs, which is not likely to reflect the ratio of the actual positive and negative chemical-protein pairs. Greater accuracy is expected by adjusting the prediction scores to reflect such a positive/negative ratio. To estimate the ratio, we first normalized the counts in each bin in the histogram (<xref ref-type="fig" rid="pcbi.1005135.g002">Fig 2A</xref>) and calculated the weights that minimize the sum of error, <italic>E</italic><sub><italic>sum</italic></sub>. <italic>E</italic><sub><italic>sum</italic></sub>(<italic>w</italic><sub>1</sub>) = &#x003a3;<sub><italic>i</italic></sub>[<italic>A</italic><sub><italic>i</italic></sub> &#x02212; {<italic>w</italic><sub>1</sub><italic>p</italic><sub><italic>i</italic></sub> + (1 &#x02212; <italic>w</italic><sub>1</sub>)<italic>N</italic><sub><italic>i</italic></sub>}]<sup>2</sup>, where <italic>w</italic><sub>1</sub> and w<sub>2</sub> are the weights on active and inactive pairs, respectively (<italic>w</italic><sub>1</sub> + <italic>w</italic><sub>2</sub> = 1.0), and <italic>A</italic><sub><italic>i</italic></sub>, <italic>p</italic><sub><italic>i</italic></sub> and <italic>N</italic><sub><italic>i</italic></sub> are the normalized counts in <italic>i</italic><sup><italic>th</italic></sup> bin of ambiguous, active and inactive pairs, respectively. The optimum adjustment weights were approximately <italic>w</italic><sub>1</sub> = 0.16, <italic>w</italic><sub>2</sub> = 0.84 (<xref ref-type="fig" rid="pcbi.1005135.g002">Fig 2B</xref>). This implies that approximately 16% of total observations are positive. Since the ratio of negative/positive is about 5.25 <inline-formula id="pcbi.1005135.e012"><alternatives><graphic xlink:href="pcbi.1005135.e012.jpg" id="pcbi.1005135.e012g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M12"><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>&#x000a0;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x000a0;</mml:mi><mml:mn>5.25</mml:mn><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, we increased the number of observations for inactive pairs in each bin by 5.25 times and rounded down. The adjusted prediction score for each bin (<italic>B</italic><sub><italic>i</italic></sub>) was calculated using the increased negative counts.</p><fig id="pcbi.1005135.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g002</object-id><label>Fig 2</label><caption><p><bold>(A) REMAP score distributions for active (blue), inactive (orange), and ambiguous (green) pairs.</bold> For each bin of raw prediction scores (x-axis, bin width = 0.05), the number of pairs found in the bin was divided by the total of the type of data (total numbers in the plot). Raw prediction scores over 1.10 were regarded as outliers and not included in the figure. Active pairs were obtained from the ZINC and the ChEMBL databases, and inactive, and ambiguous pairs were obtained from the ChEMBL database. <bold>(B)</bold> Adjusted scores for each bin of raw prediction scores (x-axis, same bin width as A). Adjustment by the counts only (blue) and adjustment with weighted counts (orange). A weight of 5.25 was given for the counts of inactive pairs as explained in the prediction score adjustment section.</p></caption><graphic xlink:href="pcbi.1005135.g002"/></fig><disp-formula id="pcbi.1005135.e013"><alternatives><graphic xlink:href="pcbi.1005135.e013.jpg" id="pcbi.1005135.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#x02211;</mml:mo><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02211;</mml:mo><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mn>5.25</mml:mn><mml:mo>&#x022c5;</mml:mo><mml:mo>&#x02211;</mml:mo><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula><p>It is noted that the prediction score adjustment was not used in the benchmark study, where no negative data were used.</p></sec><sec id="sec013"><title>Graphic analysis</title><p>Drug-drug clustered network was visualized using Cytoscape [<xref rid="pcbi.1005135.ref032" ref-type="bibr">32</xref>].</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><sec id="sec015"><title>REMAP is highly effective in predicting off-targets even for novel chemicals</title><p>We evaluated the performances of algorithms for chemicals having one, two, or more than three known targets with varying maximum chemical-chemical similarity ranges or with proteins having a certain number of known ligands (dataset prepared as explained in the <xref ref-type="sec" rid="sec002">methods and materials</xref> section). In general, the performances of both algorithms improve as the number of known ligands per protein or the maximum chemical-chemical similarity value increases.</p><p>It was noticeable that REMAP performed significantly better than PRW when there was at least one known target for a chemical whose targets are predicted (Figs <xref ref-type="fig" rid="pcbi.1005135.g003">3</xref> and <xref ref-type="fig" rid="pcbi.1005135.g004">4</xref>). REMAP showed greater than 90% recovery at the top 1% when the tested chemicals have at least one known target. All algorithms are sensitive to the number of ligands per target. The more ligands, the higher accuracy. While PRW also reached reasonably high recovery for some categories (e.g. more than 11 known ligands per proteins, or <inline-formula id="pcbi.1005135.e014"><alternatives><graphic xlink:href="pcbi.1005135.e014.jpg" id="pcbi.1005135.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x0003e;</mml:mo><mml:mn>0.6</mml:mn></mml:math></alternatives></inline-formula> of the most similar trained chemicals), REMAP showed that it is reliable for testing chemicals without high similarity to the trained chemicals (Figs <xref ref-type="fig" rid="pcbi.1005135.g003">3B</xref> and <xref ref-type="fig" rid="pcbi.1005135.g004">4B</xref>). In other words, REMAP is applicable to chemicals that are structurally distant to the chemicals already in the dataset. Except where the target proteins have 1 to 5 known ligands, REMAP performed best among the three algorithms in all cases with at least one known target for the tested chemicals (Figs <xref ref-type="fig" rid="pcbi.1005135.g003">3</xref> and <xref ref-type="fig" rid="pcbi.1005135.g004">4</xref>). In the most of cases, the differences in the performance between REMAP and other two algorithms are statistically significant. Therefore, in practice, REMAP can predict potential drug targets for chemicals with at least one known target as training data, even when the chemicals are structurally dissimilar to the training chemicals. With the optimized parameters (see below), ROC-like curves shows the general trend of performances of the three algorithms up to the top 10% of predictions (<xref ref-type="supplementary-material" rid="pcbi.1005135.s003">S3</xref> and <xref ref-type="supplementary-material" rid="pcbi.1005135.s004">S4</xref> Figs).</p><fig id="pcbi.1005135.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g003</object-id><label>Fig 3</label><caption><title>Performance comparison for REMAP (green), PRW (blue), and NRLMF (orange).</title><p>NT2 (2 known targets per chemical) datasets used for varying number of ligands (A) and chemical structural similarity (B). Performance measurement explained in the measuring prediction accuracy of REMAP by TPR vs. cutoff rank section. <bold>(A)</bold> Performance comparison on the datasets with varying number of ligands per protein. For example, the x-axis of L11to15 means that the proteins of interest have between 11 and 15 known chemicals to bind. <bold>(B)</bold> Performance comparison on the datasets with the ranges of chemical structural similarity of the tested chemicals to the trained chemicals. For instance, the x-axis of Tc0.6to0.7 means that for the tested chemicals, at least one trained chemical was found such that <inline-formula id="pcbi.1005135.e015"><alternatives><graphic id="pcbi.1005135.e015g" xlink:href="pcbi.1005135.e015"/><mml:math id="M15"><mml:mn>0.6</mml:mn><mml:mo>&#x0003c;</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula> and no trained chemical was found in greater similarity than 0.7. All TPR values are based on 10-fold cross validation. Error bars represents s.e.m. Asterisks represents statistical significance based one t-test of the 10 TPR values (* for p &#x0003c; 0.05, ** for p &#x0003c; 0.001).</p></caption><graphic xlink:href="pcbi.1005135.g003"/></fig><fig id="pcbi.1005135.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g004</object-id><label>Fig 4</label><caption><title>Performance comparison for REMAP (green), PRW (blue), and NRLMF (orange).</title><p>NT3 (3 or more known targets per chemical) datasets used for varying number of ligands (A) and chemical structural similarity (B). Performance measurement explained in the measuring prediction accuracy of REMAP by TPR vs. cutoff rank section. <bold>(A)</bold> Performance comparison on the datasets with varying number of ligands per protein. For example, the x-axis of L21more means that the proteins of interest have 21 or more known chemicals to bind. <bold>(B)</bold> Performance comparison on the datasets with the ranges of chemical structural similarity of the tested chemicals to the trained chemicals. For instance, the x-axis of Tc0.5to0.6 means that for the tested chemicals, at least one trained chemical was found such that <inline-formula id="pcbi.1005135.e016"><alternatives><graphic id="pcbi.1005135.e016g" xlink:href="pcbi.1005135.e016"/><mml:math id="M16"><mml:mn>0.5</mml:mn><mml:mo>&#x02264;</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>0.6</mml:mn></mml:math></alternatives></inline-formula> and no trained chemical was found in greater similarity than 0.6. All TPR values are based on 10-fold cross validation. Error bars represents s.e.m. Asterisks represents statistical significance based one t-test of the 10 TPR values (* for p &#x0003c; 0.05, ** for p &#x0003c; 0.001).</p></caption><graphic xlink:href="pcbi.1005135.g004"/></fig><p>As shown in Figs <xref ref-type="fig" rid="pcbi.1005135.g003">3</xref> and <xref ref-type="fig" rid="pcbi.1005135.g004">4</xref>, REMAP outperforms the state-of-the-art NRLFM algorithm in most of the tested cases. As NRLMF is sensitive to the rank parameter, we carried out optimizations to determine optimal rank and iterations for NRLMF (<xref ref-type="supplementary-material" rid="pcbi.1005135.s005">S5 Fig</xref>). The optimal rank and iterations used in the evaluation were 100 and 300, respectively. Moreover, in the current implementation, REMAP is approximately 10 times faster and uses 50% less memory than NRLMF. Consistent with the results by Liu et al. [<xref rid="pcbi.1005135.ref017" ref-type="bibr">17</xref>], the accuracies of NRLFM are significantly higher than KBMF2K, CMF, and WNNGIP in all of ZINC benchmarks. Overall, REMAP is one of the best-performing methods for the genome-wide off-target predictions.</p></sec><sec id="sec016"><title>Chemical-chemical similarity based on Tanimoto coefficient significantly helps REMAP&#x02019;s performance, while protein-protein similarity information contains significant noise</title><p>To test whether the chemical-chemical similarity matrix helps prediction, we performed 10-fold cross validation on the ZINC dataset with the contents of the chemical-chemical or the protein-protein similarity matrix controlled. In other words, about half of the non-zero chemical-chemical similarity scores were randomly chosen and removed (set to 0) for the &#x0201c;half-filled chemical similarity&#x0201d; matrix, and all entries are set to 0 for the &#x0201c;zero-filled chemical similarity&#x0201d; matrix. The predictive power of REMAP showed noticeable improvement when all available chemical-chemical similarity pairs were used, compared to the half-filled or the zero-filled similarity matrix (<xref ref-type="fig" rid="pcbi.1005135.g005">Fig 5A</xref>). Similarly, the contents of the protein-protein similarity matrix were controlled (e.g. half-filled protein similarity, and zero-filled protein similarity) while the full chemical similarity matrix was used. Unlike the chemical-chemical similarity, the protein-protein similarity information did not necessarily improve REMAP&#x02019;s predictive power. The performance was best when a half of the protein-protein similarity information was used together with the full chemical-chemical similarity matrix (<xref ref-type="fig" rid="pcbi.1005135.g005">Fig 5B</xref>). This suggests that there is significant noise in the protein-protein sequence similarity matrix although the information does help prediction. A careful examination of the BLAST-based protein-protein similarity matrix may give an insight into the design of a novel protein-protein similarity metric for drug-target binding activities (see <xref ref-type="sec" rid="sec020">discussion</xref> section).</p><fig id="pcbi.1005135.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g005</object-id><label>Fig 5</label><caption><title>Performance of REMAP according to the amount of the chemical-chemical or the protein-protein similarity information used for its 10-fold cross validation on the ZINC dataset.</title><p><bold>(A)</bold> True Positive Rate at the given cutoff rank. All available chemical and protein similarity information included (blue), a half of chemical-chemical similarity was ignored (orange), and the entire chemical-chemical similarity was ignored (green). <bold>(B)</bold> The blue line is the same as A. A half of protein-protein similarity matrix was ignored (gray), and the entire protein-protein similarity was ignored (red).</p></caption><graphic xlink:href="pcbi.1005135.g005"/></fig><p>We also performed optimization tests for <italic>p</italic><sub><italic>chem</italic></sub> and <italic>p</italic><sub><italic>prot</italic></sub> on ZINC dataset. Although the performance was slightly better when the chemical-chemical similarity importance was maximum (<xref ref-type="fig" rid="pcbi.1005135.g006">Fig 6A</xref>), the difference was too small to conclude that it is best to fix <italic>p</italic><sub><italic>chem</italic></sub> = 1. Instead, the prediction may rely too much on the chemical-chemical similarity scores. Therefore, to allow flexibility on chemical-chemical similarity information, we set <italic>p</italic><sub><italic>chem</italic></sub> = 0.75 at which the performance was almost as accurate as <italic>p</italic><sub><italic>chem</italic></sub> = 1. On the other hand, the performance was best when the protein-protein sequence similarity importance, <italic>p</italic><sub><italic>prot</italic></sub>, was 0.1 (<xref ref-type="fig" rid="pcbi.1005135.g006">Fig 6B</xref>), further supporting our claim that protein-protein sequence similarity is not an optimal choice for the prediction of a drug-target interaction. When jointly optimizing <italic>p</italic><sub><italic>chem</italic></sub> and <italic>p</italic><sub><italic>prot</italic></sub>, their optimal value is 0.25 and 0.25, respectively, in the 10-fold cross validation benchmark evaluation (<xref ref-type="supplementary-material" rid="pcbi.1005135.s002">S2B Fig</xref>).</p><fig id="pcbi.1005135.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g006</object-id><label>Fig 6</label><caption><title>Performance of REMAP according to the importance parameters for the chemical-chemical (<italic>p</italic><sub><italic>chem</italic></sub>) or the protein-protein (<italic>p</italic><sub><italic>prot</italic></sub>) similarity information used for its 10-fold cross validation on the ZINC dataset.</title><p><bold>(A)</bold> The chemical-chemical similarity importance parameter, <italic>p</italic><sub><italic>chem</italic></sub>, was controlled while <italic>p</italic><sub><italic>prot</italic></sub> = 0.1 fixed. <bold>(B)</bold> The protein-protein similarity importance parameter, <italic>p</italic><sub><italic>prot</italic></sub>, was controlled while <italic>p</italic><sub><italic>chem</italic></sub> = 0.1 fixed.</p></caption><graphic xlink:href="pcbi.1005135.g006"/></fig><p>Our result supports a recent study [<xref rid="pcbi.1005135.ref025" ref-type="bibr">25</xref>] which showed that Tanimoto coefficient is efficient for the chemical similarity calculation. Chemical fingerprint-based chemical-protein association prediction has been studied by Koutsoukas et al [<xref rid="pcbi.1005135.ref006" ref-type="bibr">6</xref>]. By defining bins (target proteins) that can contain certain chemical features based on the chemical fingerprints, Koutsoukas et al. successfully demonstrated that their algorithm, PRW, can efficiently predict unknown chemical-protein associations [<xref rid="pcbi.1005135.ref006" ref-type="bibr">6</xref>]. While the basic idea of dissecting chemical compounds into functional groups is the same, it should be noted that PRW does not consider the information obtained from proteins, as well as interactome.</p></sec><sec id="sec017"><title>REMAP is readily scalable for large chemical-protein data space</title><p>For all our tests, REMAP showed great speed without losing its accuracy. On our benchmark dataset (ZINC; 12,384 chemicals and 3,500 proteins), it took approximately 120 seconds to run 400 iterations at the rank of 200 (<italic>r</italic> = 200, <italic>p</italic><sub><italic>iter</italic></sub> = 400). The time complexity is linearly dependent on the rank (<xref ref-type="fig" rid="pcbi.1005135.g007">Fig 7A</xref>). The scalability of REMAP is superior when compared to KBMF2K, a state-of the art matrix factorization algorithm that is implemented in Matlab and has been extensively studied for predicting drug-target interactions [<xref rid="pcbi.1005135.ref016" ref-type="bibr">16</xref>]. KBMF2K took more than 10 days for the same size matrix using the same computer system in the ZINC benchmark. Moreover, REMAP was capable of higher rank factorization while KBMF2K was limited to rank 200 in our system due to the memory requirement (over 100 GB of memory). At a much higher rank (<italic>r</italic> = 2,000), less than one hour was required for REMAP on the same dataset (<xref ref-type="fig" rid="pcbi.1005135.g007">Fig 7A</xref>). Time complexity experiments on larger dataset showed that REMAP completed predictions on a dataset with 200,000 rows and 20,000 columns within 2 hours on a single core computing system with 2.88 GB of memory, demonstrating its ability to screen the whole human genome of approximately 20,000 proteins in two hours (<xref ref-type="fig" rid="pcbi.1005135.g007">Fig 7B</xref>).</p><fig id="pcbi.1005135.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g007</object-id><label>Fig 7</label><caption><title>Average running times of REMAP using a single core node with 2.88 GB of memory. All running times are in seconds.</title><p><bold>(A)</bold> Average running times on the ZINC dataset (12,384 chemicals and 3,500 proteins) according to the low-rank (<italic>r)</italic>. The linear fit with R<sup>2</sup> = 0.9856 (orange line). <bold>(B)</bold> Average running times according to the number of proteins (columns) from 1,000 to 20,000. The number of chemicals (rows) were fixed to 200,000. Error bars represent s.e.m., with n &#x02265; 15 for (A) and n &#x02265; 30 for (B).</p></caption><graphic xlink:href="pcbi.1005135.g007"/></fig></sec><sec id="sec018"><title>Large scale prediction of drug-target interactions</title><p>Since REMAP is scalable and shows superior accuracy based on our benchmark tests, we performed large scale prediction of drug-target interactions on the ZCD dataset (explained in the <xref ref-type="sec" rid="sec002">Materials and Methods</xref> section). As explained in the prediction score adjustment section, prediction scores for the active pairs were mostly located between 0.75 and 1.0 (<xref ref-type="fig" rid="pcbi.1005135.g002">Fig 2A</xref>).</p></sec><sec id="sec019"><title>Low rank profile based drug-drug similarity analysis</title><p>As expected, the percentage of pairs of chemicals that share common targets decreases with the decrease of the chemical structural similarity measured by the Tc of ECFP fingerprints (<inline-formula id="pcbi.1005135.e017"><alternatives><graphic xlink:href="pcbi.1005135.e017.jpg" id="pcbi.1005135.e017g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M17"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>). The percentage of target-sharing chemical pairs drops below 50% and 0.5% when the Tc is between 0.5 and 0.6, and less than 0.5, respectively (<xref ref-type="supplementary-material" rid="pcbi.1005135.s006">S6 Fig</xref>). Thus, it is less likely that the chemical structural similarity alone can reliably detect novel binding relations between two chemicals when the Tc is less than 0.5. It is interesting to see how REMAP performs when the chemical structural similarity fails.</p><p>We analyzed the low-rank drug profile (matrix <italic>U</italic><sub><italic>UP</italic></sub>) to check whether it represented the target-binding behavior of the drugs. When filtered by low chemical structure similarity (<inline-formula id="pcbi.1005135.e018"><alternatives><graphic xlink:href="pcbi.1005135.e018.jpg" id="pcbi.1005135.e018g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M18"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>0.5</mml:mn><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>), there are 899,871 drug-drug pairs. Among them, the profile similarity score (<inline-formula id="pcbi.1005135.e019"><alternatives><graphic xlink:href="pcbi.1005135.e019.jpg" id="pcbi.1005135.e019g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M19"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>) of 91,888 pairs is higher than 0.3. With high profile similarity (<inline-formula id="pcbi.1005135.e020"><alternatives><graphic xlink:href="pcbi.1005135.e020.jpg" id="pcbi.1005135.e020g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M20"><mml:mn>0.99</mml:mn><mml:mo>&#x02264;</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>), a total of 1,327 drug-drug pairs were found of which 1,033 pairs shared at least one common known target. <xref ref-type="supplementary-material" rid="pcbi.1005135.s007">S7 Fig</xref> shows the percentage of pairs that share the common target in different profile similarity bucket for FDA-approved drugs. This result suggests that REMAP is able to provide a chemical-protein binding profile that cannot be captured by chemical structure similarity alone.</p><p>When <inline-formula id="pcbi.1005135.e021"><alternatives><graphic xlink:href="pcbi.1005135.e021.jpg" id="pcbi.1005135.e021g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M21"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>0.3</mml:mn></mml:math></alternatives></inline-formula>, the percentage of two drugs that share a common target drops below 50% (<xref ref-type="supplementary-material" rid="pcbi.1005135.s007">S7 Fig</xref>). We constructed a drug-drug similarity network by filtering out drug pairs with <inline-formula id="pcbi.1005135.e022"><alternatives><graphic xlink:href="pcbi.1005135.e022.jpg" id="pcbi.1005135.e022g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M22"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>0.3</mml:mn></mml:math></alternatives></inline-formula>, then applied the MCL algorithm on the drug-drug network to find clusters of similar drugs. The largest cluster of drugs contained a total of 313 drugs, and their relationships to diseases were examined based on the known associations annotated in CTD [<xref rid="pcbi.1005135.ref031" ref-type="bibr">31</xref>]. As a result, we found that the drugs are mostly related to mental disorders, including hyperkinesis, dystonia, catalepsy, schizophrenia and basal ganglia diseases as the mostly related diseases. The most frequent known protein targets by the drugs were GPCRs (<xref ref-type="supplementary-material" rid="pcbi.1005135.s009">S1 Table</xref>). It is comparable that GPCRs were 1,924 times targeted while kinases were targeted only 55 times. While it is interesting to further examine the cluster, validating all of the possible drug-target pairs in the largest cluster may be inefficient.</p><p>A smaller cluster of drugs contained a total of thirty-one FDA approved drugs twenty-six of which are known to target kinases or interact with microtubule (<xref rid="pcbi.1005135.t002" ref-type="table">Table 2</xref>). Seven drugs in the cluster have not been used for cancer treatment and were found to be closely linked to the anti-cancer drugs (<xref ref-type="fig" rid="pcbi.1005135.g008">Fig 8</xref> and <xref rid="pcbi.1005135.t002" ref-type="table">Table 2</xref>). Interestingly, several of them have been tested for their anti-cancer activity. For example, colchicine (also known as colchine), an FDA approved drug for gout treatment, has been shown to have anti-proliferative effects on several human liver cancer cell lines at clinically acceptable concentrations [<xref rid="pcbi.1005135.ref033" ref-type="bibr">33</xref>]. Griseofulvin, an antifungal antibiotic drug, appears to be effective as an anti-cancer drug when used together with other anti-cancer drugs [<xref rid="pcbi.1005135.ref034" ref-type="bibr">34</xref>]. The three anthelmintic drugs, albendazole, mebendazole and niclosamide, have been studied and repurposed for their anti-cancer effects on different types of cancers. Albendazole has been shown to be effective in suppressing liver cancer cells both <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="pcbi.1005135.ref035" ref-type="bibr">35</xref>], and recently has been repurposed for ovarian cancer treatment with a bovine serum albumin-based nanoparticle drug delivery system [<xref rid="pcbi.1005135.ref036" ref-type="bibr">36</xref>]. Mebendazole showed anti-cancer activities in human lung cancer cell lines [<xref rid="pcbi.1005135.ref037" ref-type="bibr">37</xref>] and human adrenocortical cell lines [<xref rid="pcbi.1005135.ref038" ref-type="bibr">38</xref>], and it has been repurposed for colon cancer treatment [<xref rid="pcbi.1005135.ref039" ref-type="bibr">39</xref>]. Both niclosamide and mebendazole showed beneficial effects in glioblastoma in different studies [<xref rid="pcbi.1005135.ref040" ref-type="bibr">40</xref>, <xref rid="pcbi.1005135.ref041" ref-type="bibr">41</xref>]. It has been proposed to use aprepitant in combination with other compounds to improve the efficiency of temozolomide, the current standard drug for glioblastoma treatment [<xref rid="pcbi.1005135.ref042" ref-type="bibr">42</xref>]. Anti-cancer activity of carbidopa hydrate have not yet been reported. It will be interesting to experimentally validate the prediction.</p><table-wrap id="pcbi.1005135.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.t002</object-id><label>Table 2</label><caption><title>The known uses and target information for the anti-cancer drug cluster in <xref ref-type="fig" rid="pcbi.1005135.g008">Fig 8B</xref> obtained from DrugBank.</title><p>The known targets are in UniProt Accession. The target information from UniProt is in <xref ref-type="supplementary-material" rid="pcbi.1005135.s009">S1 Table</xref>.</p></caption><alternatives><graphic id="pcbi.1005135.t002g" xlink:href="pcbi.1005135.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Drug name</th><th align="center" rowspan="1" colspan="1">Approved treatment(s)</th><th align="center" rowspan="1" colspan="1">Known binding target(s)</th><th align="center" rowspan="1" colspan="1">Principal mode of action</th></tr></thead><tbody><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Albendazole</td><td align="left" rowspan="1" colspan="1">Parenchymal neurocysticercosis</td><td align="left" rowspan="1" colspan="1">F1L7U3, Q71U36, P68371, P83223</td><td align="left" rowspan="1" colspan="1">Tubulin polymerization inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Aprepitant</td><td align="left" rowspan="1" colspan="1">Antiemetic</td><td align="left" rowspan="1" colspan="1">P25103</td><td align="left" rowspan="1" colspan="1">Substance P/Neurokinin NK1 receptor antagonist</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Carbidopa hydrate</td><td align="left" rowspan="1" colspan="1">Reduce adverse effects of levodopa in Parkinson disease treatment</td><td align="left" rowspan="1" colspan="1">P20711</td><td align="left" rowspan="1" colspan="1">DOPA decarboxylase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Colchine</td><td align="left" rowspan="1" colspan="1">Gout</td><td align="left" rowspan="1" colspan="1">Q9H4B7, P07437</td><td align="left" rowspan="1" colspan="1">N/A (depolymerize microtubule)</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Griseofulvin</td><td align="left" rowspan="1" colspan="1">Ringworm infection</td><td align="left" rowspan="1" colspan="1">P10875, P87066, Q99456</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Mebendazole</td><td align="left" rowspan="1" colspan="1">Anthelmintic</td><td align="left" rowspan="1" colspan="1">Q71U36, P68371</td><td align="left" rowspan="1" colspan="1">Tubulin polymerization inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Niclosamide</td><td align="left" rowspan="1" colspan="1">Anthelmintic against tapeworm infections</td><td align="left" rowspan="1" colspan="1">P40763, O60674, P12931</td><td align="left" rowspan="1" colspan="1">disrupt oxidative phosphorylation</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Aza-epothilone B</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">Q13509</td><td align="left" rowspan="1" colspan="1">Microtubule stabilizer</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Bosutinib</td><td align="left" rowspan="1" colspan="1">Chronic Myelogenous Leukemia</td><td align="left" rowspan="1" colspan="1">P11274, P00519, P07948, P08631, P12931, P24941, Q02750, P36507, Q9Y2U5, Q13555</td><td align="left" rowspan="1" colspan="1">Tyrosin kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Cabazitaxel</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">P68366, Q9H4B7</td><td align="left" rowspan="1" colspan="1">Microtubule stabilizer</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Crizotinib</td><td align="left" rowspan="1" colspan="1">Non-small cell lung cancer</td><td align="left" rowspan="1" colspan="1">Q9UM73, P08581</td><td align="left" rowspan="1" colspan="1">Anaplastic lymphoma kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Dabrafenib</td><td align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td align="left" rowspan="1" colspan="1">P15056, P04049, P57059, Q8NG66, P53667</td><td align="left" rowspan="1" colspan="1">Inhibitor of some mutant BRAF kinases</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Dasatinib</td><td align="left" rowspan="1" colspan="1">Chronic myeloid leukemia</td><td align="left" rowspan="1" colspan="1">P00519, P12931, P29317, P06239, P07947, P10721, P09619, P51692, P24684, P06241</td><td align="left" rowspan="1" colspan="1">BRC/ABL and Src family tyrosine kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Docetaxel</td><td align="left" rowspan="1" colspan="1">Breast, ovarian and non-small cell lung cancer</td><td align="left" rowspan="1" colspan="1">Q9H4B7, P10415, P11137, P27816, P10636, O75469</td><td align="left" rowspan="1" colspan="1">Microtubule stabilizer</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Erlotinib</td><td align="left" rowspan="1" colspan="1">Non-small cell lung cancer, pancreatic cancer</td><td align="left" rowspan="1" colspan="1">P00533, O75469</td><td align="left" rowspan="1" colspan="1">N/A (EGFR inhibitor)</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Gefitinib</td><td align="left" rowspan="1" colspan="1">Non-small cell lung cancer</td><td align="left" rowspan="1" colspan="1">P00533</td><td align="left" rowspan="1" colspan="1">EGFR inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Imatinib</td><td align="left" rowspan="1" colspan="1">Chronic myelogenous leukemia</td><td align="left" rowspan="1" colspan="1">A9UF02, P10721, O43519, P04629, P07333, P16234, Q08345, P00519, P09619</td><td align="left" rowspan="1" colspan="1">Tyrosine kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Nilotinib</td><td align="left" rowspan="1" colspan="1">Various leukemias (investigational)</td><td align="left" rowspan="1" colspan="1">P00519, P10721</td><td align="left" rowspan="1" colspan="1">Tyrosine kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Paclitaxel</td><td align="left" rowspan="1" colspan="1">Lung, ovarian and breast cancers</td><td align="left" rowspan="1" colspan="1">P10415, Q9H4B7, O75469, P27816, P11137, P10636</td><td align="left" rowspan="1" colspan="1">Microtubule stabilizer</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Pazopanib</td><td align="left" rowspan="1" colspan="1">Renal cell cancer and soft tissue sarcoma</td><td align="left" rowspan="1" colspan="1">P17948, P35968, P35916, P16234, P09619, P10721, P22607, Q08881, P05230, Q9UQQ2</td><td align="left" rowspan="1" colspan="1">Tyrosine kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Ponatinib</td><td align="left" rowspan="1" colspan="1">Chronic myeloid leukemia</td><td align="left" rowspan="1" colspan="1">P00519, P11274, P10721, P07949, Q02763, P36888, P11362, P21802, P22607, P22455, P06239, P12931, P07948, P35968, P16234</td><td align="left" rowspan="1" colspan="1">Bcr-Abl tyrosine kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Regorafenib</td><td align="left" rowspan="1" colspan="1">Metastatic colorectal cancer and gastrointestinal stromal tumors</td><td align="left" rowspan="1" colspan="1">P07949, P17948, P35968, P35916, P10721, P16234, P09619, P11362, P21802, Q02763, Q16832, P04629, P29317, P04049, P15056, P15759, P42685, P00519</td><td align="left" rowspan="1" colspan="1">Multiple kinases inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Ruxolitinib</td><td align="left" rowspan="1" colspan="1">Myelofibrosis</td><td align="left" rowspan="1" colspan="1">P23458, O60674</td><td align="left" rowspan="1" colspan="1">Janus Associated Kinases (JAK) 1 and 2 inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Sorafenib</td><td align="left" rowspan="1" colspan="1">Renal cell carcinoma</td><td align="left" rowspan="1" colspan="1">P15056, P04049, P35916, P35968, P36888, P09619, P10721, P11362, P07949, P17948</td><td align="left" rowspan="1" colspan="1">Inhibitor of Raf kinase, PDGF, VEGFR 2 and 3</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Sunitinib</td><td align="left" rowspan="1" colspan="1">Renal cell carcinoma and gastrointestinal stromal tumor</td><td align="left" rowspan="1" colspan="1">P09619, P17948, P10721, P35968, P35916, P36888, P07333, P16234</td><td align="left" rowspan="1" colspan="1">Multi-targeted receptor tyrosine kinase inhibitor</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Trametinib</td><td align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td align="left" rowspan="1" colspan="1">Q02750, P36507</td><td align="left" rowspan="1" colspan="1">Allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 and 2</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Vandetanib</td><td align="left" rowspan="1" colspan="1">Broad range tumor types</td><td align="left" rowspan="1" colspan="1">P15692, P00533, Q13882, Q02763</td><td align="left" rowspan="1" colspan="1">Inhibitor of VEGFR</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Vinblastine</td><td align="left" rowspan="1" colspan="1">Breast, testicular cancers, lymphomas, neuroblastoma</td><td align="left" rowspan="1" colspan="1">Q71U36, P07437, Q9UJT1, P23258, Q9UJT0, P05412</td><td align="left" rowspan="1" colspan="1">N/A (inhibition of mitosis at metaphase)</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Vincristine</td><td align="left" rowspan="1" colspan="1">Acute lymphocytic leukemia, lymphomas, neuroblastoma, rhabdomyosarcoma</td><td align="left" rowspan="1" colspan="1">P07437, P68366</td><td align="left" rowspan="1" colspan="1">N/A (inhibition of mitosis at metaphase)</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Vindesine</td><td align="left" rowspan="1" colspan="1">Acute leukemia, malignant lymphoma, Hodgkin&#x02019;s disease, acute erythraemia, acute panmyelosis</td><td align="left" rowspan="1" colspan="1">Q9H4B7</td><td align="left" rowspan="1" colspan="1">Inhibition of mitosis at metaphase</td></tr><tr><td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">Vinorelbine</td><td align="left" rowspan="1" colspan="1">Non-small cell lung carcinoma</td><td align="left" rowspan="1" colspan="1">P07437</td><td align="left" rowspan="1" colspan="1">N/A (inhibition of mitosis at metaphase)</td></tr></tbody></table></alternatives></table-wrap><fig id="pcbi.1005135.g008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005135.g008</object-id><label>Fig 8</label><caption><p><bold>(A) The drug clusters created based on the profile similarity with the anti-cancer drug cluster in the middle (darker blue grid). (B)</bold> The clusters of FDA-approved anti-cancer drugs. A set of 25 known anti-cancer drugs (blue boxes), and another set of 7 FDA-approved drugs that are closely linked to the former set but have not yet been approved for anti-cancer treatment (darker blue boxes). Procedures explained in the drug-target interaction profile analysis for drug repurposing section.</p></caption><graphic xlink:href="pcbi.1005135.g008"/></fig></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><sec id="sec021"><title>REMAP improves the predictive power of off-target prediction and drug repurposing</title><p>Our extensive benchmark studies show that REMAP outperforms existing algorithms in most of the cases for the off-target prediction. Compared with other state-of-the-art matrix factorization algorithms, the predictive power of REMAP comes from several improvements. First, we formulated the drug-target prediction as a one-class collaborative filtering problem; thus the negative data are not required for the training. Second, <italic>a priori</italic> knowledge including known negative data can be incorporated into the matrix factorization with imputation and weighting. Finally, using global imputation and weighting, the algorithm is computationally efficient without significantly sacrificing its performance.</p><p>The efficiency and effectiveness of REMAP allows us to predict proteome-wide target binding profiles of hundreds of thousands of chemicals. As the proteome-wide target binding profile is more correlated with phenotypic response than a single target binding, REMAP will facilitate linking molecular interactions in the test tube with <italic>in vivo</italic> drug activity. When using a multi-target binding profile predicted by REMAP as the signature of a chemical compound, seven drugs were found to be associated with anti-cancer therapeutics, although they do not have detectable chemical structural similarity. Among them, the anti-cancer activity of six drugs was supported by experimental evidences. Thus, REMAP could be a useful tool for drug repurposing.</p></sec><sec id="sec022"><title>Remaining issues and future directions</title><p>Although REMAP showed its high potential on genome-wide off-target predictions as discussed above, two issues remain: the <italic>cold start</italic> problem and suboptimal protein-protein similarity metrics. Similar to matrix factorization algorithms such as NRLMF, REMAP suffers from <italic>cold start</italic> problem, also known as <italic>new user</italic> or <italic>new item</italic> problem. In other words, it is difficult to recommend a product for a <italic>new user</italic> if the <italic>new user</italic> has never purchased or reviewed a product in the database [<xref rid="pcbi.1005135.ref028" ref-type="bibr">28</xref>]. For novel chemicals that do not have any known target in the dataset, REMAP did not show better performance than PRW. Moreover, if the target of the novel chemical has 5 or fewer known ligands, the recovery of REMAP is lower than 0.5 (<xref ref-type="supplementary-material" rid="pcbi.1005135.s008">S8A Fig</xref>). When the novel chemical is similar to those chemicals in the database, the recovery of REMAP reached above 90% (<xref ref-type="supplementary-material" rid="pcbi.1005135.s008">S8B Fig</xref>). These results suggest that, in practice, existing matrix factorization-based methods, including REMAP, are not the optimal choice if the chemicals of interest do not have any known target. To resolve this issue, it is possible to design an algorithm that combines the benefits of PRW or other algorithms with REMAP. The use of confidence weights and <italic>a priori</italic> imputation makes it straightforward for REMAP to incorporate additional information. In addition, the time and memory efficiency of REMAP makes it possible to apply active learning to overcome the <italic>cold start</italic> problem [<xref rid="pcbi.1005135.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pcbi.1005135.ref046" ref-type="bibr">46</xref>].</p><p>The suboptimal performance of REMAP may arise from the lack of molecular-level biochemical details in deriving the protein-protein similarity metrics. When testing the ZINC dataset, we found that REMAP performs better as lower weight was assigned for protein-protein sequence similarity data (<xref ref-type="fig" rid="pcbi.1005135.g006">Fig 6B</xref>). In addition, the predictive power of REMAP improved when about half of the randomly selected protein-protein similarity scores were removed, further confirming that noise confounds relating global sequence similarity to ligand binding (<xref ref-type="fig" rid="pcbi.1005135.g005">Fig 5B</xref>). It is not surprising that proteins with similar sequences do not necessarily bind to similar chemicals, as protein-ligand interaction is governed by the spatial organization of amino acid residues in the protein structure [<xref rid="pcbi.1005135.ref047" ref-type="bibr">47</xref>]. Amino acid mutations/post-translational modifications and conformational dynamics may alter the binding of the ligand through direct modification of the ligand binding site or allosteric interaction. A protein may also consist of multiple binding sites that accommodate different types of ligands. Thus, two proteins with high sequence similarity do not necessarily bind the same ligands because the two proteins may possess different 3D conformations, especially in their binding pockets [<xref rid="pcbi.1005135.ref047" ref-type="bibr">47</xref>]. In contrast, two proteins with low sequence similarity can bind to the same ligands if their binding pockets are similar [<xref rid="pcbi.1005135.ref048" ref-type="bibr">48</xref>, <xref rid="pcbi.1005135.ref049" ref-type="bibr">49</xref>]. The binding site similarity can be a more biologically sensitive measure of protein-protein similarity for the off-target prediction [<xref rid="pcbi.1005135.ref050" ref-type="bibr">50</xref>&#x02013;<xref rid="pcbi.1005135.ref055" ref-type="bibr">55</xref>]. Such work is on-going.</p></sec><sec id="sec023"><title>Conclusion</title><p><italic>In silico</italic> drug-target screening is an essential step to reduce costly experimental steps in drug development. In this study, we showed that dual-regularized one-class collaborative filtering algorithm, a class of computational methods frequently used in user-item preference recommendations, may be applied to drug-target association predictions. Our study presents REMAP, a collaborative filtering algorithm with capability of running whole human genome-level predictions within two hours. Other studies on some types of cancer treatment support our algorithm&#x02019;s ability to capture drug-drug similarities based on both the drug-target interaction profile and the chemical structural similarity. Our study shows the limitation of REMAP in evaluating new chemicals or accommodating biochemical details. Further development of the computational tools for better prediction is needed.</p></sec></sec><sec sec-type="supplementary-material" id="sec024"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pcbi.1005135.s001"><label>S1 Fig</label><caption><title>True Positive Rate (TPR) determined in 10-fold cross validation of ZINC benchmark set.</title><p>The e-value cutoffs for protein-protein similarity calculation based on BLAST sequence comparison. The lower the cutoff, the more stringent in similarity detection.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s001.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s002"><label>S2 Fig</label><caption><title>True Positive Rate (TPR) determined in 10-fold cross validation of ZINC benchmark set.</title><p>(A) parameter selection for rank <italic>r</italic> and the number of maximum iterations. (B) parameter selection for <italic>p</italic><sub><italic>chem</italic></sub> and <italic>p</italic><sub><italic>prot</italic></sub>.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s002.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s003"><label>S3 Fig</label><caption><title>ROC-like curves comparing the performances of REMAP (green), PRW (blue), and NRLMF (orange) based on the number of known ligands (L).</title><p>True Positive Rate (TPR) at y-axis vs. cutoff row-rank for the prediction up to the top 10% (350<sup>th</sup>).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s003.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s004"><label>S4 Fig</label><caption><title>ROC-like curves comparing the performances of REMAP (green), PRW (blue), and NRLMF (orange) based on the maximum chemical structural similarity (Tc).</title><p>True Positive Rate (TPR) at y-axis vs. cutoff row-rank for the prediction up to the top 10% (350<sup>th</sup>).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s004.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s005"><label>S5 Fig</label><caption><title>The performance of NRLMF on the ZINC datasets with varying parameters (r and iter are equivalent to the low-rank parameter, <italic>r</italic>, and the number of iterations, <italic>p</italic><sub><italic>iter</italic></sub>, respectively).</title><p>The best performance was by r = 100, iter = 300 (yellow bars), which was chosen for the optimized parameters. (A) The optimization on NT1 dataset with varying number of ligands per target. (B) The optimization on NT2 dataset with varying number of ligands per target. (C) The optimization on NT3 dataset with varying number of ligands per target.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s005.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s006"><label>S6 Fig</label><caption><title>The percent of chemical-chemical pairs that share at least one common target in ZINC_ChEMBL_DrugBank dataset.</title><p>The value for the first bar with the chemical-chemical similarity range between 0.0 and 0.5 is 0.314%.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s006.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s007"><label>S7 Fig</label><caption><title>The percent of FDA-approved drug-drug pairs that share at least one common target in ZINC_ChEMBL_DrugBank dataset.</title><p>(A) The percent of drug-drug pairs for chemical structure similarity ranges for all FDA-approved drug-drug pairs. (B) The percent of drug-drug pairs for low-rank profile similarity ranges for drug-drug pairs having structure similarity less than 0.5.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s007.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s008"><label>S8 Fig</label><caption><title>Performance comparison for REMAP (green), PRW (blue), and NRLMF (orange).</title><p>NT1 (1 known target per chemical) datasets used for varying number of ligands (A) and chemical structural similarity (B). Performance measurement explained in the measuring prediction accuracy of REMAP by TPR vs. cutoff rank section. <bold>(A)</bold> Performance comparison on the datasets with varying number of ligands per protein. For example, the x-axis of L1to5 means that the proteins of interest have 1 to 5 known chemicals to bind. <bold>(B)</bold> Performance comparison on the datasets with the ranges of chemical structural similarity of the tested chemicals to the trained chemicals. For instance, the x-axis of Tc0.5to0.6 means that for the tested chemicals, at least one trained chemical was found such that <inline-formula id="pcbi.1005135.e023"><alternatives><graphic xlink:href="pcbi.1005135.e023.jpg" id="pcbi.1005135.e023g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M23"><mml:mn>0.5</mml:mn><mml:mo>&#x02264;</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>0.6</mml:mn></mml:math></alternatives></inline-formula> and no trained chemical was found in greater similarity than 0.6. All TPR values are based on 10-fold cross validation. Error bars represents s.e.m. Asterisks represents statistical significance based one t-test of the 10 TPR values (* for p &#x0003c; 0.05, ** for p &#x0003c; 0.001).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1005135.s008.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s009"><label>S1 Table</label><caption><title>The drugs and target information for the largest cluster in <xref ref-type="fig" rid="pcbi.1005135.g007">Fig 7</xref>.</title><p>(XLSX)</p></caption><media xlink:href="pcbi.1005135.s009.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1005135.s010"><label>S2 Table</label><caption><title>The protein IDs and annotations for <xref rid="pcbi.1005135.t002" ref-type="table">Table 2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1005135.s009">S1 Table</xref>. Obtained from UniProt.</title><p>(XLSX)</p></caption><media xlink:href="pcbi.1005135.s010.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We acknowledge Miriam Cohen, Ph.D. for proof-reading the manuscript.</p></ack><ref-list><title>References</title><ref id="pcbi.1005135.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Dickson</surname><given-names>M</given-names></name>, <name><surname>Gagnon</surname><given-names>JP</given-names></name>. <article-title>The cost of new drug discovery and development</article-title>. <source>Discovery Medicine</source>. <year>2009</year>;<volume>4</volume>(<issue>22</issue>):<fpage>172</fpage>&#x02013;<lpage>9</lpage> .<pub-id pub-id-type="pmid">20704981</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Kinnings</surname><given-names>SL</given-names></name>, <name><surname>Bourne</surname><given-names>PE</given-names></name>. <article-title>Novel computational approaches to polypharmacology as a means to define responses to individual drugs</article-title>. <source>Annual review of pharmacology and toxicology</source>. <year>2012</year>;<volume>52</volume>:<fpage>361</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010611-134630</pub-id>
<pub-id pub-id-type="pmid">22017683</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Bowes</surname><given-names>J</given-names></name>, <name><surname>Brown</surname><given-names>AJ</given-names></name>, <name><surname>Hamon</surname><given-names>J</given-names></name>, <name><surname>Jarolimek</surname><given-names>W</given-names></name>, <name><surname>Sridhar</surname><given-names>A</given-names></name>, <name><surname>Waldron</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</article-title>. <source>Nature reviews Drug discovery</source>. <year>2012</year>;<volume>11</volume>(<issue>12</issue>):<fpage>909</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3845</pub-id>
<pub-id pub-id-type="pmid">23197038</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Butler</surname><given-names>D</given-names></name>, <name><surname>Callaway</surname><given-names>E</given-names></name>. <article-title>Scientists in the dark after French clinical trial proves fatal</article-title>. <source>Nature</source>. <year>2016</year>;<volume>529</volume>(<issue>7586</issue>):<fpage>263</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/nature.2016.19189</pub-id>
<pub-id pub-id-type="pmid">26791697</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Haggarty</surname><given-names>SJ</given-names></name>, <name><surname>Koeller</surname><given-names>KM</given-names></name>, <name><surname>Wong</surname><given-names>JC</given-names></name>, <name><surname>Butcher</surname><given-names>RA</given-names></name>, <name><surname>Schreiber</surname><given-names>SL</given-names></name>. <article-title>Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays</article-title>. <source>Chemistry &#x00026; biology</source>. <year>2003</year>;<volume>10</volume>(<issue>5</issue>):<fpage>383</fpage>&#x02013;<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/S1074-5521(03)00095-4</pub-id> .<pub-id pub-id-type="pmid">12770821</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Koutsoukas</surname><given-names>A</given-names></name>, <name><surname>Lowe</surname><given-names>R</given-names></name>, <name><surname>KalantarMotamedi</surname><given-names>Y</given-names></name>, <name><surname>Mussa</surname><given-names>HY</given-names></name>, <name><surname>Klaffke</surname><given-names>W</given-names></name>, <name><surname>Mitchell</surname><given-names>JB</given-names></name>, <etal>et al</etal>
<article-title>In silico target predictions: defining a benchmarking data set and comparison of performance of the multiclass na&#x000ef;ve bayes and parzen-rosenblatt window</article-title>. <source>Journal of chemical information and modeling</source>. <year>2013</year>;<volume>53</volume>(<issue>8</issue>):<fpage>1957</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1021/ci300435j</pub-id>
<pub-id pub-id-type="pmid">23829430</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Keiser</surname><given-names>MJ</given-names></name>, <name><surname>Roth</surname><given-names>BL</given-names></name>, <name><surname>Armbruster</surname><given-names>BN</given-names></name>, <name><surname>Ernsberger</surname><given-names>P</given-names></name>, <name><surname>Irwin</surname><given-names>JJ</given-names></name>, <name><surname>Shoichet</surname><given-names>BK</given-names></name>. <article-title>Relating protein pharmacology by ligand chemistry</article-title>. <source>Nat Biotechnol</source>. <year>2007</year>;<volume>25</volume>(<issue>2</issue>):<fpage>197</fpage>&#x02013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1284</pub-id>
<pub-id pub-id-type="pmid">17287757</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Cruz-Monteagudo</surname><given-names>M</given-names></name>, <name><surname>Medina-Franco</surname><given-names>JL</given-names></name>, <name><surname>Perez-Castillo</surname><given-names>Y</given-names></name>, <name><surname>Nicolotti</surname><given-names>O</given-names></name>, <name><surname>Cordeiro</surname><given-names>MN</given-names></name>, <name><surname>Borges</surname><given-names>F</given-names></name>. <article-title>Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde?</article-title>
<source>Drug Discov Today</source>. <year>2014</year>;<volume>19</volume>(<issue>8</issue>):<fpage>1069</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2014.02.003</pub-id> .<pub-id pub-id-type="pmid">24560935</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref009"><label>9</label><mixed-citation publication-type="other">Dahl GE, Jaitly N, Salakhutdinov R. Multi-task Neural Networks for QSAR Predictions. arXiv:14061231 [statML]. 2014.</mixed-citation></ref><ref id="pcbi.1005135.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>J</given-names></name>, <name><surname>Sheridan</surname><given-names>RP</given-names></name>, <name><surname>Liaw</surname><given-names>A</given-names></name>, <name><surname>Dahl</surname><given-names>GE</given-names></name>, <name><surname>Svetnik</surname><given-names>V</given-names></name>. <article-title>Deep neural nets as a method for quantitative structure-activity relationships</article-title>. <source>J Chem Inf Model</source>. <year>2015</year>;<volume>55</volume>(<issue>2</issue>):<fpage>263</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1021/ci500747n</pub-id> .<pub-id pub-id-type="pmid">25635324</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref011"><label>11</label><mixed-citation publication-type="other">Ramsundar B, Kearnes S, Riley P, Webster D, Kon- erding D, Pande V. Massively Multitask Networks for Drug Discovery. arXiv:150202072 [statML]. 2015.</mixed-citation></ref><ref id="pcbi.1005135.ref012"><label>12</label><mixed-citation publication-type="other">Unterthiner T, Mayr A, Klambauer G, Hochreiter S. Toxicity Prediction Using Deep Learning. arXiv:150301445 [statML]. 2015.</mixed-citation></ref><ref id="pcbi.1005135.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>van Laarhoven</surname><given-names>T</given-names></name>, <name><surname>Nabuurs</surname><given-names>SB</given-names></name>, <name><surname>Marchiori</surname><given-names>E</given-names></name>. <article-title>Gaussian interaction profile kernels for predicting drug&#x02013;target interaction</article-title>. <source>Bioinformatics</source>. <year>2011</year>;<volume>27</volume>(<issue>21</issue>):<fpage>3036</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btr500</pub-id>
<pub-id pub-id-type="pmid">21893517</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>van Laarhoven</surname><given-names>T</given-names></name>, <name><surname>Marchiori</surname><given-names>E</given-names></name>. <article-title>Predicting drug-target interactions for new drug compounds using a weighted nearest neighbor profile</article-title>. <source>PloS one</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e66952</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0066952</pub-id>
<pub-id pub-id-type="pmid">23840562</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref015"><label>15</label><mixed-citation publication-type="other">Zheng X, Ding H, Mamitsuka H, Zhu S, editors. Collaborative matrix factorization with multiple similarities for predicting drug-target interactions. Proceedings of the 19th ACM SIGKDD international conference on Knowledge discovery and data mining; 2013: ACM.</mixed-citation></ref><ref id="pcbi.1005135.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>G&#x000f6;nen</surname><given-names>M</given-names></name>. <article-title>Predicting drug&#x02013;target interactions from chemical and genomic kernels using Bayesian matrix factorization</article-title>. <source>Bioinformatics</source>. <year>2012</year>;<volume>28</volume>(<issue>18</issue>):<fpage>2304</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts360</pub-id>
<pub-id pub-id-type="pmid">22730431</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>M</given-names></name>, <name><surname>Miao</surname><given-names>C</given-names></name>, <name><surname>Zhao</surname><given-names>P</given-names></name>, <name><surname>Li</surname><given-names>X-L</given-names></name>. <article-title>Neighborhood Regularized Logistic Matrix Factorization for Drug-Target Interaction Prediction</article-title>. <source>PLoS Comput Biol</source>. <year>2016</year>;<volume>12</volume>(<issue>2</issue>):<fpage>e1004760</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1004760</pub-id>
<pub-id pub-id-type="pmid">26872142</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>JJ</given-names></name>, <name><surname>Sterling</surname><given-names>T</given-names></name>, <name><surname>Mysinger</surname><given-names>MM</given-names></name>, <name><surname>Bolstad</surname><given-names>ES</given-names></name>, <name><surname>Coleman</surname><given-names>RG</given-names></name>. <article-title>ZINC: a free tool to discover chemistry for biology</article-title>. <source>Journal of chemical information and modeling</source>. <year>2012</year>;<volume>52</volume>(<issue>7</issue>):<fpage>1757</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1021/ci3001277</pub-id>
<pub-id pub-id-type="pmid">22587354</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Bento</surname><given-names>AP</given-names></name>, <name><surname>Gaulton</surname><given-names>A</given-names></name>, <name><surname>Hersey</surname><given-names>A</given-names></name>, <name><surname>Bellis</surname><given-names>LJ</given-names></name>, <name><surname>Chambers</surname><given-names>J</given-names></name>, <name><surname>Davies</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>The ChEMBL bioactivity database: an update</article-title>. <source>Nucleic acids research</source>. <year>2013</year>:gkt1031 <pub-id pub-id-type="doi">10.1093/nar/gkt1031</pub-id> .<pub-id pub-id-type="pmid">24214965</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Wishart</surname><given-names>DS</given-names></name>, <name><surname>Knox</surname><given-names>C</given-names></name>, <name><surname>Guo</surname><given-names>AC</given-names></name>, <name><surname>Cheng</surname><given-names>D</given-names></name>, <name><surname>Shrivastava</surname><given-names>S</given-names></name>, <name><surname>Tzur</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>DrugBank: a knowledgebase for drugs, drug actions and drug targets</article-title>. <source>Nucleic acids research</source>. <year>2008</year>;<volume>36</volume>(<issue>suppl 1</issue>):<fpage>D901</fpage>&#x02013;<lpage>D6</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkm958</pub-id> .<pub-id pub-id-type="pmid">18048412</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Thiessen</surname><given-names>PA</given-names></name>, <name><surname>Bolton</surname><given-names>EE</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Fu</surname><given-names>G</given-names></name>, <name><surname>Gindulyte</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>PubChem substance and compound databases</article-title>. <source>Nucleic acids research</source>. <year>2015</year>:gkv951 <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id> .<pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref022"><label>22</label><mixed-citation publication-type="journal"><collab>Consortium U</collab>. <article-title>UniProt: a hub for protein information</article-title>. <source>Nucleic acids research</source>. <year>2014</year>:gku989 <pub-id pub-id-type="doi">10.1093/nar/gku989</pub-id> .<pub-id pub-id-type="pmid">25348405</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Sun</surname><given-names>J</given-names></name>, <name><surname>Guan</surname><given-names>J</given-names></name>, <name><surname>Zheng</surname><given-names>J</given-names></name>, <name><surname>Zhou</surname><given-names>S</given-names></name>. <article-title>Improving compound&#x02013;protein interaction prediction by building up highly credible negative samples</article-title>. <source>Bioinformatics</source>. <year>2015</year>;<volume>31</volume>(<issue>12</issue>):<fpage>i221</fpage>&#x02013;<lpage>i9</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btv256</pub-id>
<pub-id pub-id-type="pmid">26072486</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref024"><label>24</label><mixed-citation publication-type="other">Yao Y, Tong H, Yan G, Xu F, Zhang X, Szymanski BK, et al., editors. Dual-regularized one-class collaborative filtering. Proceedings of the 23rd ACM International Conference on Conference on Information and Knowledge Management; 2014: ACM.</mixed-citation></ref><ref id="pcbi.1005135.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Bajusz</surname><given-names>D</given-names></name>, <name><surname>R&#x000e1;cz</surname><given-names>A</given-names></name>, <name><surname>H&#x000e9;berger</surname><given-names>K</given-names></name>. <article-title>Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations?</article-title>
<source>Journal of Cheminformatics</source>. <year>2015</year>;<volume>7</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1186/s13321-015-0069-3</pub-id>
<pub-id pub-id-type="pmid">25705261</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref026"><label>26</label><mixed-citation publication-type="journal"><collab>ChemAxon</collab>. <article-title>Screen was used for generating pharmacophore descriptors and screening structures</article-title>, <source>JChem</source> 15.3.2.0. <year>2015</year>.</mixed-citation></ref><ref id="pcbi.1005135.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Camacho</surname><given-names>C</given-names></name>, <name><surname>Coulouris</surname><given-names>G</given-names></name>, <name><surname>Avagyan</surname><given-names>V</given-names></name>, <name><surname>Ma</surname><given-names>N</given-names></name>, <name><surname>Papadopoulos</surname><given-names>J</given-names></name>, <name><surname>Bealer</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>BLAST+: architecture and applications</article-title>. <source>BMC bioinformatics</source>. <year>2009</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-10-421</pub-id> .<pub-id pub-id-type="pmid">19118496</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Su</surname><given-names>X</given-names></name>, <name><surname>Khoshgoftaar</surname><given-names>TM</given-names></name>. <article-title>A survey of collaborative filtering techniques</article-title>. <source>Advances in artificial intelligence</source>. <year>2009</year>;<volume>2009</volume>:<fpage>4</fpage>
<pub-id pub-id-type="doi">10.1155/2009/421425</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Van Dongen</surname><given-names>S</given-names></name>. <article-title>A cluster algorithm for graphs</article-title>. <source>Report-Information systems</source>. <year>2000</year>;(<issue>10</issue>):<fpage>1</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="pcbi.1005135.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Enright</surname><given-names>AJ</given-names></name>, <name><surname>Van Dongen</surname><given-names>S</given-names></name>, <name><surname>Ouzounis</surname><given-names>CA</given-names></name>. <article-title>An efficient algorithm for large-scale detection of protein families</article-title>. <source>Nucleic acids research</source>. <year>2002</year>;<volume>30</volume>(<issue>7</issue>):<fpage>1575</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1093/nar/30.7.1575</pub-id>
<pub-id pub-id-type="pmid">11917018</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Davis</surname><given-names>AP</given-names></name>, <name><surname>Grondin</surname><given-names>CJ</given-names></name>, <name><surname>Lennon-Hopkins</surname><given-names>K</given-names></name>, <name><surname>Saraceni-Richards</surname><given-names>C</given-names></name>, <name><surname>Sciaky</surname><given-names>D</given-names></name>, <name><surname>King</surname><given-names>BL</given-names></name>, <etal>et al</etal>
<article-title>The Comparative Toxicogenomics Database's 10th year anniversary: update 2015</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>;<volume>43</volume>(<issue>Database issue</issue>):<fpage>D914</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku935</pub-id>
<pub-id pub-id-type="pmid">25326323</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Shannon</surname><given-names>P</given-names></name>, <name><surname>Markiel</surname><given-names>A</given-names></name>, <name><surname>Ozier</surname><given-names>O</given-names></name>, <name><surname>Baliga</surname><given-names>NS</given-names></name>, <name><surname>Wang</surname><given-names>JT</given-names></name>, <name><surname>Ramage</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome research</source>. <year>2003</year>;<volume>13</volume>(<issue>11</issue>):<fpage>2498</fpage>&#x02013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
<pub-id pub-id-type="pmid">14597658</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>Z-Y</given-names></name>, <name><surname>Wu</surname><given-names>C-C</given-names></name>, <name><surname>Chuang</surname><given-names>Y-H</given-names></name>, <name><surname>Chuang</surname><given-names>W-L</given-names></name>. <article-title>Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma</article-title>. <source>Life sciences</source>. <year>2013</year>;<volume>93</volume>(<issue>8</issue>):<fpage>323</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2013.07.002</pub-id>
<pub-id pub-id-type="pmid">23871804</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>P</given-names></name>, <name><surname>Rathinasamy</surname><given-names>K</given-names></name>, <name><surname>Mohan</surname><given-names>R</given-names></name>, <name><surname>Panda</surname><given-names>D</given-names></name>. <article-title>Microtubule assembly dynamics: an attractive target for anticancer drugs</article-title>. <source>IUBMB life</source>. <year>2008</year>;<volume>60</volume>(<issue>6</issue>):<fpage>368</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1002/iub.42</pub-id>
<pub-id pub-id-type="pmid">18384115</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Pourgholami</surname><given-names>M</given-names></name>, <name><surname>Woon</surname><given-names>L</given-names></name>, <name><surname>Almajd</surname><given-names>R</given-names></name>, <name><surname>Akhter</surname><given-names>J</given-names></name>, <name><surname>Bowery</surname><given-names>P</given-names></name>, <name><surname>Morris</surname><given-names>D</given-names></name>. <article-title>In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole</article-title>. <source>Cancer letters</source>. <year>2001</year>;<volume>165</volume>(<issue>1</issue>):<fpage>43</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3835(01)00382-2</pub-id>
<pub-id pub-id-type="pmid">11248417</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Noorani</surname><given-names>L</given-names></name>, <name><surname>Stenzel</surname><given-names>M</given-names></name>, <name><surname>Liang</surname><given-names>R</given-names></name>, <name><surname>Pourgholami</surname><given-names>MH</given-names></name>, <name><surname>Morris</surname><given-names>DL</given-names></name>. <article-title>Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model</article-title>. <source>J Nanobiotechnol</source>. <year>2015</year>;<volume>13</volume>(<issue>1</issue>):<fpage>25</fpage>
<pub-id pub-id-type="doi">10.1186/s12951-015-0082-8</pub-id> .<pub-id pub-id-type="pmid">25890381</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Mukhopadhyay</surname><given-names>T</given-names></name>, <name><surname>Sasaki</surname><given-names>J-I</given-names></name>, <name><surname>Ramesh</surname><given-names>R</given-names></name>, <name><surname>Roth</surname><given-names>JA</given-names></name>. <article-title>Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo</article-title>. <source>Clinical cancer research</source>. <year>2002</year>;<volume>8</volume>(<issue>9</issue>):<fpage>2963</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">12231542</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Martarelli</surname><given-names>D</given-names></name>, <name><surname>Pompei</surname><given-names>P</given-names></name>, <name><surname>Baldi</surname><given-names>C</given-names></name>, <name><surname>Mazzoni</surname><given-names>G</given-names></name>. <article-title>Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice</article-title>. <source>Cancer chemotherapy and pharmacology</source>. <year>2008</year>;<volume>61</volume>(<issue>5</issue>):<fpage>809</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-007-0538-0</pub-id>
<pub-id pub-id-type="pmid">17581752</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Nygren</surname><given-names>P</given-names></name>, <name><surname>Frykn&#x000e4;s</surname><given-names>M</given-names></name>, <name><surname>&#x000c5;gerup</surname><given-names>B</given-names></name>, <name><surname>Larsson</surname><given-names>R</given-names></name>. <article-title>Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer</article-title>. <source>Journal of cancer research and clinical oncology</source>. <year>2013</year>;<volume>139</volume>(<issue>12</issue>):<fpage>2133</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-013-1539-5</pub-id>
<pub-id pub-id-type="pmid">24135855</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Bai</surname><given-names>R-Y</given-names></name>, <name><surname>Staedtke</surname><given-names>V</given-names></name>, <name><surname>Aprhys</surname><given-names>CM</given-names></name>, <name><surname>Gallia</surname><given-names>GL</given-names></name>, <name><surname>Riggins</surname><given-names>GJ</given-names></name>. <article-title>Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme</article-title>. <source>Neuro-oncology</source>. <year>2011</year>:nor077 <pub-id pub-id-type="doi">10.1093/neuonc/nor077</pub-id> .<pub-id pub-id-type="pmid">21764822</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Wieland</surname><given-names>A</given-names></name>, <name><surname>Trageser</surname><given-names>D</given-names></name>, <name><surname>Gogolok</surname><given-names>S</given-names></name>, <name><surname>Reinartz</surname><given-names>R</given-names></name>, <name><surname>H&#x000f6;fer</surname><given-names>H</given-names></name>, <name><surname>Keller</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Anticancer effects of niclosamide in human glioblastoma</article-title>. <source>Clinical Cancer Research</source>. <year>2013</year>;<volume>19</volume>(<issue>15</issue>):<fpage>4124</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2895</pub-id>
<pub-id pub-id-type="pmid">23908450</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Kast</surname><given-names>RE</given-names></name>, <name><surname>Karpel-Massler</surname><given-names>G</given-names></name>, <name><surname>Halatsch</surname><given-names>M-E</given-names></name>. <article-title>CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide</article-title>. <source>Oncotarget</source>. <year>2014</year>;<volume>5</volume>(<issue>18</issue>):<fpage>8052</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2408</pub-id>
<pub-id pub-id-type="pmid">25211298</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Fujiwara</surname><given-names>Y</given-names></name>, <name><surname>Yamashita</surname><given-names>Y</given-names></name>, <name><surname>Osoda</surname><given-names>T</given-names></name>, <name><surname>Asogawa</surname><given-names>M</given-names></name>, <name><surname>Fukushima</surname><given-names>C</given-names></name>, <name><surname>Asao</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Virtual screening system for finding structurally diverse hits by active learning</article-title>. <source>Journal of chemical information and modeling</source>. <year>2008</year>;<volume>48</volume>(<issue>4</issue>):<fpage>930</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1021/ci700085q</pub-id>
<pub-id pub-id-type="pmid">18351729</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref044"><label>44</label><mixed-citation publication-type="other">Grave K, Ramon J, Raedt L. Active Learning for High Throughput Screening. In: Jean-Fran J-F, Berthold MR, Horv&#x000e1;th T, editors. Discovery Science: 11th International Conference, DS 2008, Budapest, Hungary, October 13&#x02013;16, 2008 Proceedings. Berlin, Heidelberg: Springer Berlin Heidelberg; 2008. p. 185&#x02013;96.</mixed-citation></ref><ref id="pcbi.1005135.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Lang</surname><given-names>T</given-names></name>, <name><surname>Flachsenberg</surname><given-names>F</given-names></name>, <name><surname>von Luxburg</surname><given-names>U</given-names></name>, <name><surname>Rarey</surname><given-names>M</given-names></name>. <article-title>Feasibility of Active Machine Learning for Multiclass Compound Classification</article-title>. <source>Journal of Chemical Information and Modeling</source>. <year>2016</year>;<volume>56</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00332</pub-id>
<pub-id pub-id-type="pmid">26740007</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Warmuth</surname><given-names>MK</given-names></name>, <name><surname>Liao</surname><given-names>J</given-names></name>, <name><surname>R&#x000e4;tsch</surname><given-names>G</given-names></name>, <name><surname>Mathieson</surname><given-names>M</given-names></name>, <name><surname>Putta</surname><given-names>S</given-names></name>, <name><surname>Lemmen</surname><given-names>C</given-names></name>. <article-title>Active Learning with Support Vector Machines in the Drug Discovery Process</article-title>. <source>Journal of Chemical Information and Computer Sciences</source>. <year>2003</year>;<volume>43</volume>(<issue>2</issue>):<fpage>667</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1021/ci025620t</pub-id>
<pub-id pub-id-type="pmid">12653536</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Creixell</surname><given-names>P</given-names></name>, <name><surname>Palmeri</surname><given-names>A</given-names></name>, <name><surname>Miller</surname><given-names>CJ</given-names></name>, <name><surname>Lou</surname><given-names>HJ</given-names></name>, <name><surname>Santini</surname><given-names>CC</given-names></name>, <name><surname>Nielsen</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Unmasking determinants of specificity in the human kinome</article-title>. <source>Cell</source>. <year>2015</year>;<volume>163</volume>(<issue>1</issue>):<fpage>187</fpage>&#x02013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.08.057</pub-id>
<pub-id pub-id-type="pmid">26388442</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>H</given-names></name>, <name><surname>Sassano</surname><given-names>MF</given-names></name>, <name><surname>Roth</surname><given-names>BL</given-names></name>, <name><surname>Shoichet</surname><given-names>BK</given-names></name>. <article-title>A pharmacological organization of G protein-coupled receptors</article-title>. <source>Nature methods</source>. <year>2013</year>;<volume>10</volume>(<issue>2</issue>):<fpage>140</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2324</pub-id>
<pub-id pub-id-type="pmid">23291723</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Bourne</surname><given-names>PE</given-names></name>. <article-title>Detecting evolutionary relationships across existing fold space, using sequence order-independent profile&#x02013;profile alignments</article-title>. <source>Proceedings of the National Academy of sciences</source>. <year>2008</year>;<volume>105</volume>(<issue>14</issue>):<fpage>5441</fpage>&#x02013;<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0704422105</pub-id> .<pub-id pub-id-type="pmid">18385384</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Bourne</surname><given-names>PE</given-names></name>. <article-title>In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators</article-title>. <source>PLoS Comput Biol</source>. <year>2007</year>;<volume>3</volume>(<issue>11</issue>):<fpage>e217</fpage> Epub 2007/12/07. 07-PLCB-RA-0389 [pii] <pub-id pub-id-type="doi">10.1371/journal.pcbi.0030217</pub-id> .<pub-id pub-id-type="pmid">18052534</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Kinnings</surname><given-names>SL</given-names></name>, <name><surname>Liu</surname><given-names>N</given-names></name>, <name><surname>Buchmeier</surname><given-names>N</given-names></name>, <name><surname>Tonge</surname><given-names>PJ</given-names></name>, <name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Bourne</surname><given-names>PE</given-names></name>. <article-title>Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis</article-title>. <source>PLoS Comput Biol</source>. <year>2009</year>;<volume>5</volume>(<issue>7</issue>):<fpage>e1000423</fpage> Epub 2009/07/07. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000423</pub-id> .<pub-id pub-id-type="pmid">19578428</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Bourne</surname><given-names>PE</given-names></name>. <article-title>Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors</article-title>. <source>PLoS Comput Biol</source>. <year>2009</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e1000387</fpage> Epub 2009/05/14. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000387</pub-id> .<pub-id pub-id-type="pmid">19436720</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Durrant</surname><given-names>JD</given-names></name>, <name><surname>Amaro</surname><given-names>RE</given-names></name>, <name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Urbaniak</surname><given-names>MD</given-names></name>, <name><surname>Ferguson</surname><given-names>MA</given-names></name>, <name><surname>Haapalainen</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology</article-title>. <source>PLoS Comput Biol</source>. <year>2010</year>;<volume>6</volume>(<issue>1</issue>):<fpage>e1000648</fpage> Epub 2010/01/26. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000648</pub-id> .<pub-id pub-id-type="pmid">20098496</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Evangelidis</surname><given-names>T</given-names></name>, <name><surname>Xie</surname><given-names>L</given-names></name>, <name><surname>Bourne</surname><given-names>PE</given-names></name>. <article-title>Drug Discovery Using Chemical Systems Biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of Nelfinavir</article-title>. <source>PLoS Comput Biol</source>. <year>2011</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e1002037</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1002037</pub-id>
<pub-id pub-id-type="pmid">21552547</pub-id></mixed-citation></ref><ref id="pcbi.1005135.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Ho Sui</surname><given-names>SJ</given-names></name>, <name><surname>Lo</surname><given-names>R</given-names></name>, <name><surname>Fernandes</surname><given-names>AR</given-names></name>, <name><surname>Caulfield</surname><given-names>MD</given-names></name>, <name><surname>Lerman</surname><given-names>JA</given-names></name>, <name><surname>Xie</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence</article-title>. <source>Int J Antimicrob Agents</source>. <year>2012</year>;<volume>40</volume>(<issue>3</issue>):<fpage>246</fpage>&#x02013;<lpage>51</lpage>. Epub 2012/07/24. S0924-8579(12)00210-5 [pii] <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.05.009</pub-id> .<pub-id pub-id-type="pmid">22819149</pub-id></mixed-citation></ref></ref-list></back></article>